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ABSTRACT 
The role of marine n-3 polyunsaturated fatty acids (PUFAs) in colorectal carcinogenesis 
has been investigated in many epidemiological studies; however, the epidemiological evidence is 
inconclusive. A potential explanation is due to competing products of n-3 PUFAs metabolism. 
Anti-inflammatory eicosanoids, products of n-3 PUFAs metabolism through cyclooxygenase 
(COX) enzymes, could inhibit inflammatory responses, which have a protective effect against 
colorectal cancer. Alternatively, malondialdehyde (MDA) and 4-hydroxy-2-hexenal (4-HHE), 
lipid peroxidation products of marine n-3 PUFAs, could be mutagenic. It has been suggested that 
glutathione S-transferases (GSTs) are involved in removing lipid peroxidation products. 
Therefore, we investigated whether GST genotypes (i.e., GSTT1, GSTM1) modified the marine 
n-3 PUFAs-colorectal cancer association using a nested case-control study within the Singapore 
Chinese Health Study. With 469 incident colorectal cancer cases and 1,167 noncases, we 
observed the effect modification of combined GSTT1 and GSTM1 positive genotypes with 
marine n-3 PUFAs on colorectal cancer (p for interaction < 0.01), and with the ratio of marine n-
3 to n-6 PUFAs on colorectal cancer (p for interaction = 0.01). An inverse association of marine 
n-3 PUFAs with colorectal cancer was observed among those with high activity GST genotypes 
(i.e., combined GSTM1 and GSTT1 positive genotype) [Odds ratio (OR) for Q4 vs. Q1 = 0.57, 
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95% CI = 0.32-1.01, p for trend <0.05]; however, a positive association was observed among 
those with one or more GST null genotypes [OR for Q4 vs. Q1 = 1.49, 95% CI = 1.00-2.23, p for 
trend = 0.01]. Among those with one or more GST null genotypes, a positive association was 
also shown for the ratio of marine n-3 to n-6 PUFAs and colorectal cancer [OR for Q4 vs. Q1 = 
1.64, 95% CI = 1.09-2.37, p for trend < 0.01], although no statistically significant association 
was observed for high activity GST genotypes. Our results suggest the role of GSTT1 and 
GSTM1 in the association between marine n-3 PUFAs and colorectal cancer. This finding 
provided a point to consider GST genotypes in the marine n-3 PUFAs-colorectal cancer 
association in the population. It is important for further public health intervention program to 
consider this interaction while intervening on the population. 
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1.0  INTRODUCTION 
1.1 EPIDEMIOLOGY OF COLORECTAL CANCER 
Colorectal cancer is the third most common cancer in men (746,000 new cases per year) 
and the second in women (614,000 new cases per year) worldwide.1 There is a 10-fold variation 
in incidence across regions worldwide, regardless of sex, where highest age-standardized rate per 
100,000 is in Australia/New Zealand (44.8 in men and 32.2 in women), whereas the lowest rate 
is in Western Africa (4.5 in men and 3.8 in women).1 Approximately 55% of cases occur in more 
developed regions.1 The highest incidence rates are among western regions (i.e., Australia/New 
Zealand, Europe, and Northern America), whereas the lowest incidence rates are among 
populations in south and central Asia and Africa.2 This difference indicates the association 
between the incidence of colorectal cancer and economic growth. Increasing incidence among 
populations as they transition from developing to developed economies, like Singapore since 
independence in 1965, also reflects the relationship between colorectal cancer and economic 
growth. In Singapore, for men, the incidence for colorectal cancer increased from 27.2 to 37.2 
and 40.9 per 100,000 per year for the time period of 1975-1979, 1990-1994, and 2000-2004, 
respectively. Similar trends were seen in women, from 21.7 to 30.1 to 29.3 per 100,000 per year 
for the same three time periods.3 In 2014, the rates have dropped slightly to 38.2 in men and 26.7 
in women. However, colorectal cancer remains the most common cancer in men and second 
most common in women among Singapore Chinese, comprising 17.8% and 13.9% of total 
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cancers during the period 2010-2014 in men and women, respectively.3 Given that economic 
growth correlates with urbanization and adoption of western lifestyle and behavior (e.g., diets 
high in red meat, low in vegetables and fiber, and less active lifestyles)4,5, it is a special 
opportunity to investigate the association between different aspects of lifestyle (e.g., dietary 
factors) and colorectal cancer risk among countries such as Singapore during the transition 
period. 
1.2 RISK AND PREVENTIVE FACTORS FOR COLORECTAL CANCER 
1.2.1  Non-dietary factors 
Family History. Family history is a well-established risk factor for colorectal cancer.6 The 
estimates of relative risk (RR) for those who had a first-degree relative with colorectal cancer 
was 2.25 [95% confidence interval (CI) = 2.00-2.53] compared to those without a first degree 
relative with colorectal cancer, according to a 2001 meta-analysis of 27 studies (20 case-control 
and 7 cohort studies).7 In addition, the RR of colorectal cancer was greater for those first-degree 
relatives of cases diagnosed at younger ages: 3.87 (95% CI = 2.40-6.22) among first-degree 
relatives of cases diagnosed before age 45, 2.25 (95% CI = 1.85-2.72) among first-degree 
relatives of cases diagnosed between ages 45 and 59, and 1.82 (95% CI = 1.47-2.25) among first-
degree relatives of cases diagnosed after 59 year-old, compared with those without a first degree 
relative having colorectal cancer.7 The increased risk among people with family history may 
reflect inherited genetic susceptibility in the occurrence of this cancer.  
Cigarette Smoking. Results from a 2009 meta-analysis of 36 prospective studies (2 nested case-
control and 34 prospective cohort studies), showed that compared with nonsmokers, current 
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smokers had a RR of 1.15 (95% CI = 1.00-1.32), and former smokers had a RR of colorectal 
cancer of 1.20 (95% CI = 1.04-1.38).8 Additionally, among ever smokers, the dose of cigarette 
consumption (RR = 1.38 per 40 cigarettes/day), smoking duration (RR = 1.20 for a 40-year 
increase in duration), and earlier age of initiation (RR = 1.04 for every 10-year earlier age when 
start smoking) were associated with an increased risk of colorectal cancer.8 The magnitude of 
association was greater for rectal cancer than colon cancer.8  
Similar results have been observed from the Singapore Chinese Health Study.  Compared 
with never smokers, number of cigarettes per day (RR for ≥13 cigarettes/day = 1.71, 95% CI = 
1.28-2.28), age at starting to smoke (RR for <15 year-old = 2.34, 95% CI = 1.63-3.36),  and 
number of years of smoking (RR for ≥40 years = 1.85, 95% CI = 1.36-2.52) were significantly 
associated with rectal cancer; however, no statistically significant association has been found for 
colon cancer.9 A smoking exposure index was created where ‘heavy’ smoker was defined as 
those who started to smoke before 15 years of age and smoked 13 or more cigarettes per day; all 
other ever smokers were classified as ‘light’ smokers.9 Number of years of smoking was not 
included in the index, because it was highly correlated with age at starting to smoke. Compared 
with never smokers, heavy and light smokers were at increased risk for rectal cancer with RRs of 
2.64 (95% CI = 1.77-3.96) and 1.43 (95% CI = 1.10-1.87), respectively, whereas a statistically 
significant association was not found for colon cancer.9 
Alcohol Consumption. A 2011 meta-analysis of 19 studies (12 case-control studies and 7 cohort 
studies) showed that moderate drinkers (2-3 drinks/day) and heavy drinkers (≥4 drinks/day), 
compared with non-/occasional drinkers, had RRs of 1.21 (95% CI = 1.13-1.28) and 1.52 (95% 
CI = 1.27-1.81) for colorectal cancer, respectively.10 There was a dose-dependent relationship. 
Compared with nondrinkers, the RRs of 10, 25, 50, and 100 g/day of alcohol intake were 1.07 
4 
 
(95% CI = 1.04-1.10), 1.18 (95% CI = 1.12-1.25), 1.38 (95% CI = 1.28-1.50), and 1.82 (95% CI 
= 1.41-2.35), respectively. Among Singapore Chinese, heavy drinking was positively associated 
with colorectal cancer risk [RR for <7 drinks/week vs. nondrinkers = 0.96 (95% CI = 0.72-1.25); 
RR for ≥7 drinks/week vs. nondrinkers=1.84 (95% CI = 1.31-2.58), p for trend = 0.0004].9 
Obesity. Based on a 2009 meta-analysis, every 5 kg/m2 increase in BMI is associated with a 
24% higher risk of colon cancer in men (RR = 1.24, 95% CI = 1.20-1.28), and a 9% higher risk 
of colon cancer in women (RR = 1.09, 95% CI = 1.04-1.14).11 The magnitude of RR was weaker 
for rectal cancer, which was 1.09 (95% CI = 1.06-1.12) for men and 1.02 (95% CI = 0.99-1.04) 
for women.11 This positive association could be explained by the relationship between obesity 
and insulin resistance.12,13 Higher blood insulin levels, as a result of obesity-induced insulin 
resistance, may stimulate the growth of colorectal tumor cells.14 Although obesity is associated 
with higher risk of colorectal cancer, there is some evidence suggesting that a low BMI is not 
associated with decreased risk.  In the Singapore Chinese Health Study, the mean BMI is low 
(i.e., 23.1 kg/m2) and only 10.4% are with BMI ≥27.5 kg/m2. Compared with normal BMI (i.e., 
21.5≤BMI<24.5), the HR for BMI <18.5 kg/m2 was 1.03 (95% CI = 0.80-1.32) and the HR for 
BMI ≥27.5 kg/m2 was 1.25 (95% CI = 1.01-1.55).15  These results suggest that normal weight 
may be more preferable than underweight or overweight in terms of risk of developing colorectal 
cancer.15 
Diabetes Mellitus. According to a meta-analysis of 17 cohort studies, compared with those 
without DM, the RR for those who with a history of DM was 1.28 (95% CI = 1.19-1.39).16 
Obesity may be a confounder of this association, because of its role in inducing the insulin 
resistance syndrome as stated above12; however, the association between DM and colorectal 
cancer remained statistically significant after adjusting for BMI in several prospective studies.17-
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19 Among Singapore Chinese, a history of physician-diagnosed diabetes was associated with 
50% increased risk for colorectal cancer among men (RR = 1.5, 95% CI = 1.2-2.1) and a 40% 
increased risk among women (RR = 1.4, 95% CI = 1.0-1.9), after adjusting for covariates 
including BMI.20  
Treatments for diabetes are also associated with colorectal cancer risk. Insulin treatment 
may increase the risk of colorectal cancer among those who have been diagnosed with DM: 
among type 2 DM patients, long-term insulin treatment has found increasing the risk of 
colorectal cancer (OR = 1.21 with 95% CI = 1.03-1.42 for each incremental year of insulin 
therapy).21 This relationship is not surprising, considering the growth promoting effect of insulin. 
Treatment with metformin may reduce the incidence of cancer, including colorectal cancer.22-24 
The interplay between DM and its treatment may need further investigation.  
Physical activity. Generally, the increase in total physical activity is associated with a decreased 
risk of colorectal cancer.25 Its effect on colorectal cancer could be related to its influence on 
insulin sensitivity and insulin level.13 The intensity and duration of physical activity may have 
different effects on colorectal cancer risk. A meta-analysis of 19 cohort studies showed that, 
compared with sedentary activity, those who were highly active had a reduction in risk of 
colorectal cancer [RRs for highest vs. none for men for occupational and recreational activities 
were 0.79 (95% CI = 0.72-0.87) and 0.78 (95% CI = 0.68-0.91); RRs highest vs. none for 
women for occupational and recreational physical activities were 1.12 (95% CI = 0.85-1.47) and 
0.71 (95% CI = 0.57-0.88)], but no statistically significant result has been shown for total 
physical activity.26 According to another 2015 meta-analysis (10 prospective studies), a potential 
dose-response has been shown for the association between leisure time physical activity and 
colorectal cancer risk: compared with those who were inactive, people had 10, 20 and 40 
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metabolic equivalents of energy hours per week (MET-h/wk) has a reduction in colorectal cancer 
risk by 8% (95% CI=0.85-1.00), 15% (95% CI=0.79-0.92), and 14% (95% CI=0.80-0.94), 
respectively.27 As people are very likely to change their physical activity patterns at different 
stages of life, one case-control study in Australia investigated if being physical activity over 
multiple life stages would be more beneficial than those who were always no/low active or only 
active in specific age periods. The results showed that people who were vigorously physically 
active throughout their lifetime had a lower risk for both of distal colon cancer and rectal cancer, 
compared with those who were always no/low active or only active in specific age periods; the 
association of vigorously physical activity and proximal colon cancer was not statistically 
significant.28 Therefore, physical activity is beneficial, but the magnitude of this protective effect 
may vary by type (e.g., occupational or recreational physical activity) and how long people keep 
it as a habit through lifetime. Among Singapore Chinese, strenuous activity or vigorous work 
was associated with lower risk of colon cancer [RR for ≥ 1.5 hours/week vs. <1.5 hours/week 
strenuous physical activity and/or vigorous work = 0.61 (95% CI = 0.42-0.88)], but the 
association of rectal cancer was not statistically significant.29  
Nonsteroidal Anti-inflammatory drugs (NSAIDs). The overall reduction in risk with NSAID 
use was suggested for both of colon and rectal cancer (colon: OR = 0.72, 95% CI = 0.62- 0.85; 
rectal: OR = 0.73, 95% CI = 0.61-0.88).30 Regular use of aspirin was associated with a 27% 
decrease in colorectal cancer risk (RR = 0.73, 95% CI = 0.67-0.79) among observational 
studies.31 According to a meta-analysis of four clinical trials, the hazard ratio of those who were 
assigned to aspirin versus those who were assigned to placebo was 0.76 (95% CI = 0.60-0.96) for 
colon cancer and 0.90 (95% CI = 0.64-1.30) for rectal cancer.32 Nonaspirin NSAIDs (e.g., 
Ibuprofen) also had preventive effect against colorectal cancer (OR = 0.94, 95% CI = 0.90-
7 
 
0.98).33 The major mechanism of this preventive effect is ability of NSAIDs to inhibit the 
cyclooxygenase (COX) enzymes. COX enzymes are involved in the synthesis of prostaglandin 
(PG). The inhibition of COX enzymes would decrease the PG synthesis. The products of PG 
synthesis are involved in the progress of colorectal cancer.34 
1.2.2  Dietary factors 
Red meat and processed meat. In addition to the factors above, diet plays an important role in 
the development of colorectal cancer.35 There is convincing evidence of the positive associations 
of increased red and processed meat consumption, and inverse association of increased dietary 
fiber with colorectal cancer. 36 36 In 2015,  red meat was classified as “probably carcinogenic to 
humans” (Group 2A) and processed meat was classified as “carcinogenic to humans” (Group 1) 
by International Agency for Research on Cancer  (IARC).37 In a systematic review of 
prospective studies with results for meat intake and colorectal cancer risk, the RR per 100 g per 
day of red meat was 1.17 (95% CI=1.05-1.31), and the RR per 50 g per day of processed meat 
was 1.18 (95% CI=1.10-1.28).38  
Dietary fiber. Dietary fiber intake was inversely associated with the risk for colorectal cancer. 36 
Based on results from a meta-analysis of 25 prospective studies, the RR per 10 g per day intake 
of fiber was 0.90 (95% CI=0.86-0.94). The dietary fiber-colorectal cancer risk association varied 
by the food source of fiber. The RRs for each 10 g/day intake were 0.93 (95% CI = 0.82-1.05), 
0.98 (95% CI = 0.91-1.06), 0.90 (95% CI = 0.86-0.94) and 0.62 (95% CI = 0.27-1.42) for fiber 
from fruit, vegetable, cereal, and legumes, respectively.39 Fiber from legumes may be most 
strongly associated with decreased risk, although the RR is not statistically significant. 
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Fish intake. Fish intake has been suggested as a protective factor for colorectal cancer by World 
Cancer Research Fund and American Institute for Cancer Research.36 One meta-analysis (20 
prospective cohort studies) in 2014 demonstrated an inverse association for which fish intake 
decreased the colorectal cancer risk by 7% (RR for highest consumption vs. lowest consumption 
= 0.93, 95% CI = 0.87-0.99).40 However, only 3 out of 20 studies showed a statistically 
significantly inverse association.41-43 Kato et al. reported that fish and shellfish intake was 
inversely associated with colorectal cancer risk [RR for Q4 vs. Q1 = 0.49 (95% CI = 0.27-0.89)] 
among females in the U.S.43 The inverse association between fish intake and colorectal cancer 
risk has also been reported by Hall et al. among U.S. men: compared to those who had fish less 
than 1 time/week, those who had fish 5 or more times/week had 37% lower risk [RR for ≥5 
times/week vs. <1 time/week = 0.63 (95% CI = 0.42-0.95)].41 Another study in 10 European 
countries showed the RR for those who had ≥80g/d fish was with 31% lower risk than those who 
had <10g/d fish.42  None of other 17 cohort studies which were conducted across the U.S.44-48, 
Europe42,49-55, Australia56, Japan57,58, and China59 showed a statistically significant result for the 
association between fish intake and colorectal cancer.  
One possible reason for different results could be the association between fish intake and 
colorectal cancer varies by subsite. Based on a meta-analysis, the summary RR of colon cancer 
for highest vs. lowest fish intake is 0.95 (95% CI = 0.91-0.98), and the summary RR of rectal 
cancer is 0.85 (95% CI = 0.75-0.95).40 However, colon and rectal cancer were not analyzed 
separately by most studies, and the prevalence of colon cancer was greater than rectal cancer. 
Another reason could be the different within-study variation in intake. Studies reporting 
statistically significant association had greater within-study variation. For instance, Hall et al. 
compared the risk of colorectal cancer for ≥5 times/week versus <1 time/week.41 This variation 
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was greater than most studies using frequency.44,50,53,56 The different dietary measurement tools 
used could be another reason.  
1.3 DIETARY POLYUNSATURATED FATTY ACIDS (PUFAS) AND 
COLORECTAL CANCER 
1.3.1  Dietary PUFAs 
Long-chain polyunsaturated fatty acids (LC-PUFAs, fatty acids which contain 14-22 
carbon atoms) could be classified into n-6 and n-3 PUFAs, according to the position of the first 
double bond from the methyl end group of fatty acid.60 Linoleic acid (LA), an n-6 PUFA, and 
alpha-linolenic acid (ALA), an n-3 PUFA, are essential fatty acids that must be obtained from 
the diet.61 LA and ALA are mainly found in vegetable oil and nuts.62 
Blood concentrations of fatty acids reflect dietary intake and endogenous synthesis.63 
From LA and ALA, humans can synthesize other LC-PUFAs. Longer chain n-6 PUFAs, such as 
dihomo-γ-linolenic acid (DGLA) and arachidonic acid (AA), are synthesized from LA (Figure 
1). Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are synthesized from ALA 
through desaturation and elongation. A competitive relationship exists between the synthesis of 
longer n-3 and n-6 PUFAs from ALA and LA, because the same elongase and desaturase 
enzymes are involved in these processes.64 However, the ability to elongate ALA to the longer 
chain EPA and DHA in human body is very limited, therefore EPA and DHA are mainly 
obtained through dietary sources.65 EPA and DHA are mainly found in seafood, especially oily 
fish (e.g., salmon, tuna, mackerel, and herring).62,66 Per 100g cooked fish or seafood would 
provide approximately 0.2g-2.0g EPA plus DHA.62 
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1.3.2  The association between dietary PUFAs and colorectal cancer 
The relationship between dietary PUFAs and colorectal cancer risk differs by the specific 
PUFA structural classification (e.g., number and position of double bonds). The intake of n-6 
PUFAs has been suggested to increase the risk of colorectal cancer, because AA could be 
converted by cyclooxygenase (COX) 1 and COX-2 enzymes into prostaglandins, of which 
Prostaglandin E2 and Prostaglandin I2 have been linked to colorectal cancer (Figure 2).67 
However, this association has not been found in epidemiological studies.48,68-72 One study in the 
U.S. reported that the RR of colorectal cancer for n-6 PUFAs was 0.89 [RR for ≥12.0 g/d vs. 
<8.0 g/d = 0.89 (95% CI = 0.70-1.12)] for women, and 1.17 [RR for ≥14.0 g/d vs. <10.0 g/d = 
1.17 (95% CI = 0.95-1.79)] for men.68 Women’s Health Study showed similar results: compared 
with the lowest quintile of intake (median = 3.8% total energy), highest quintile (median = 7.6% 
total energy) of n-6 PUFAs intake has a RR of 1.6 (95% CI = 0.98-2.60).70 Among Chinese 
women, the association between total n-6 PUFAs intake and colorectal cancer was not 
statistically significant either [RR highest quintile vs. lowest quintile = 1.10 (95% CI = 0.57-
2.12)].69 Among Singapore Chinese, n-6 PUFAs were not statistically significantly associated 
with either of localized [RR for Q4 vs. Q1 = 0.92 (95% CI = 0.68-1.23)] and advanced [RR for 
Q4 vs. Q1 = 0.90 (95% CI = 0.70-1.59)] colorectal cancer.71 Therefore, the association with n-6 
PUFAs intake for colorectal cancer risk needs further investigation.  
Dietary n-3 PUFAs are hypothesized to have a protective effect against colorectal cancer, 
due in part to their effect of inhibiting the expression of COX-2.73 Another potential mechanism 
is through alteration in the cellular redox state and  increasing oxidative stress.74 The 
peroxidation process of PUFAs generates reactive oxygen species (ROS) such as the superoxide 
radical.74 The elevation of intracellular ROS levels induced by n-3 PUFAs has been hypothesized 
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to induce cancer cell apoptosis.75 Inconsistent results were found in epidemiological studies with 
respect to the relationship between the intake of total n-3 PUFAs and risk of developing 
colorectal cancer. Based on a systematic review, the RR for colorectal cancer incidence of the 
highest versus the lowest category was 0.91 (95% CI = 0.70-1.19) for total n-3 fatty acids intake 
(3 studies).76  
The role of marine n-3 PUFAs (i.e., EPA and DHA) has been considered individually, 
given that the food sources of EPA and DHA are different from ALA (the most common n-3 
PUFAs), and ALA is commonly used for energy. The association with marine n-3 PUFAs has 
been investigated by many studies across different countries (Table 1). Hall et al. reported a 
negative association between marine n-3 PUFAs and colorectal cancer risk [RR for Q4 vs. Q1 = 
0.76 (95% CI = 0.59- 0.98), p for trend = 0.02] among men in the US.41 A study in Japan found a 
negative association of marine n-3 PUFAs with colorectal cancer risk among women [RR for Q5 
vs. Q1 = 0.60 (95% CI = 0.31-1.14), p for trend = 0.04].72 In the Singapore Chinese Health 
Study, a positive association was reported between marine n-3 PUFAs intake and advanced 
colorectal cancer (Dukes C or D) [Hazard ratio (HR) for Q4 vs. Q1 = 1.33, 95%CI = 1.05-1.70, p 
for trend = 0.01].71 Similar results were reported from a prospective study among a U.S. 
population (HR Tertile 3 vs. Tertile 1 = 1.44, 95% CI = 1.02-2.04, p for trend = 0.04).77 
According to a systematic review, the RR for colorectal cancer incidence of the highest versus 
the lowest category was 0.92 (95% CI = 0.74-1.13) for DHA, and 0.84 (95% CI = 0.69-1.01) for 
EPA.78 Overall, the association of marine n-3 PUFAs and colorectal cancer is not supported by 
most epidemiologic studies. Null results have been reported by different countries and regions, 
including people had low (e.g., US44,48,68,79,80) and high (e.g., Sweden81) fish intake. There are 
some possible reasons. First, marine n-3 PUFAs has been suggested by animal data playing a 
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role in inhibiting colorectal tumor initiation.82 Among Singapore Chinese, the positive 
association between marine n-3 PUFAs and colorectal cancer was only observed among people 
who had a follow-up period ≤ 5 years [RR for Q4 vs. Q1 = 1.35 (95% CI = 1.01-1.80)].71 Among 
people who had a follow up period > 10 years, there is a potentially inverse association [RR for 
Q4 vs. Q1 = 0.77 (95% CI = 0.47-1.26)].71 It is also possible that the inconsistent results for 
dietary marine n-3 PUFAs and colorectal cancer, despite convincing evidence from biological 
experiments, reflect that it is necessary to take another important factor, such as genetic 
susceptibility, into consideration. 
1.3.3  The mechanistic rationale for a relationship between dietary PUFAs and colorectal 
cancer development 
The endogenous metabolism of LC-PUFAs involves multiple pathways.73 COX-1 and 
COX-2 enzymes are involved in the final stage of LC-PUFA metabolism into prostaglandins and 
leukotrienes.73 The products of AA through the COX pathway are pro-inflammatory eicosanoids, 
while the products of EPA/DHA are eicosanoids with anti-inflammatory properties.73 PGE2 and 
PGI2, the products of AA via COX pathway, have been involved in colorectal cancer 
carcinogenesis.83 EPA has an inhibitory effect on the COX enzyme, thus reducing the synthesis 
of pro-inflammatory AA products.73   
In a parallel, competing lipid peroxidation pathway, LC-PUFAs are excellent targets for 
oxidation. Both n-3 and n-6 PUFAs are susceptible to oxidation by reactive oxygenated 
species.73 With more doubled bonds, marine n-3 PUFAs, especially DHA, are more susceptible 
to oxidation than AA.84 With their difference in structure, the profiles of their lipid peroxidation 
products might be different. The lipid peroxidation products of AA include malondialedehyde 
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(MDA) and 4-hydroxy-2-nonenal (4-HNE), while the lipid peroxidation products of EPA and 
DHA are MDA and 4-hydroxy-2-hexenal (HHE).85  
The lipid peroxidation products such as MDA have high capability of reaction with 
proteins and DNA that leads to the formation of adducts.86 Given that DNA is the target 
molecule for carcinogens, DNA adducts may contribute to the etiology of human cancers.87 The 
role of 4-HNE in inducing significant DNA damage has been demonstrated by both of in vivo88 
and in vitro89 studies. 4-HNE has been suggested as the most toxic product of lipid peroxidation, 
and its carcinogenic effect in normal cells has also been demonstrated.73,86 The function of 4-
HHE has been less investigated, but it might have mutagenicity.88 In general, higher levels of 
these chemicals may increase the colorectal cancer risk. 
The inconsistent results in epidemiologic studies investigating the relationship between 
dietary n-3 and n-6 PUFAs and colorectal cancer risk may be influenced by the unmeasured 
heterogeneity of genetic susceptibility of the lipid peroxidation pathway. For example, in 
Singapore Chinese, single nucleotide polymorphisms (SNPs) in DNA repair genes PARP 
Val762Ala modified the effect of marine n-3 PUFAs on colorectal cancer risk among rectal 
cancer cases (p-interaction=0.016) but not colon cancer cases.90 This study suggested that high 
intake of marine n-3 PUFAs might increase risk for rectal cancer among subjects with less 
efficient PARP function.90 
1.3.4  Glutathione S-transferase (GST) enzyme 
The GST enzymes can be divided into five main classes: alpha (GSTA), mu (GSTM), pi 
(GSTP), theta (GSTT) and zeta (GSTZ), which belong to a super family of phase II 
detoxification enzymes. They have been linked to the metabolism of a wide range of chemicals, 
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some of which are associated with higher risk of cancer.91,92 Additionally, they are polymorphic 
enzymes with interindividual variations in enzymatic level and activity.93 The genes coding for 
the enzymes GSTM, GSTT and GSTP are polymorphic, and the genotypes of GSTM1 null and 
GSTT1 null result in the absence of GSTM1 and GSTT1 expression, and GSTP1 AB/BB leads to 
a decreased enzymatic activity of protein.91,94,95 These genotypes lead to a low activity in GST 
enzymes. Considering the role of GST enzymes in metabolism, the association of GST genotypes 
with colorectal cancer has been investigated by many studies in Asian populations: 
nonsignificant associations have been found by most studies96-99, but an increased colorectal 
cancer risk for GSTT1 null vs. GSTT1 positive has also been reported.100 
The role of GST genotypes in modifying the association of some factors and colorectal 
cancer has been suggested. For example, it has been suggested that isothiocyanates (ITCs) have 
an interaction with GST genotypes. The effect of ITCs, a chemical in cruciferous vegetable that 
may have chemopreventive activity against cancer, depends on an individual GST genotype, as 
found by A.Seow et al. in Singapore Chinese. An inverse association between ITCs and 
colorectal cancer has been shown among those who possessed low activity GST genotypes [OR 
high (>median) versus low (≤median) intake of ITCs = 0.43, 95% CI = 0.20-0.96] (low activity 
GST genotypes have been defined as GSTM1 and GSTT1 null), but absent among people with 
high activity GST genotypes (OR high vs. low intake of ITCs = 0.92, 95% CI = 0.64-1.32).99 In 
addition, GST genotypes have been reported interacting with cigarette smoking in terms of 
colorectal cancer risk.92 Subjects who possessed more low activity GST genotypes would be 
more susceptible to smoking-induced colorectal carcinogenesis.92 The ORs for heavy smokers 
vs. never smokers were 5.43 (95% CI = 2.22-13.23), 2.43 (95% CI = 1.01-5.86), and 1.34 (95% 
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CI = 0.38-4.76) for those who possessed 2+, 1 and 0 low activity GST genotypes (GSTM1 null, 
GSTT1 null, GSTP1 AB/BB).92 
1.4 A RATIONALE FOR GST GENOTYPE MODIFICATION ON THE 
RELATIONSHIP BETWEEN DIETARY PUFAS AND RISK OF COLORECTAL 
CANCER 
The above evidence suggests a gene-environment interaction of GSTs on the association 
between dietary PUFAs and colorectal cancer, given that harmful lipid peroxidation product, 
especially 4-HNE, could undergo detoxification through the process of glutathione-associated 
metabolism by GST enzymes.86,101,102  
One related study which was a nested-case control study conducted in the Netherlands 
reported that the presence of GSTM1 gene may modify the association of fish consumption and 
risk for colorectal cancer.50 According to their result, among those with GSTM1 positive, the OR 
of colorectal cancer for fish intake >4 times per month versus 0-1 times was 0.5 (95% CI = 0.2-
1.1). The OR for those who had GSTM1 null was 0.9 (95% CI = 0.4-1.7). Although not 
statistically significant, there was a trend that the inverse association of fish intake with 
colorectal cancer was shown among those who possessed positive GSTM1 genotype, but not 
among those with GSTM1 null.50 
  As marine n-3 PUFAs have been considered as the main contributor to the effect of fish 
intake on colorectal cancer, a reasonable hypothesis is that, among individuals with high activity 
GST genotypes (i.e., GSTT1 positive, GSTM1 positive, GSTP1 AA), the inverse association 
between marine n-3 PUFAs and colorectal cancer risk would be stronger than among those who 
possessed low activity GST genotypes (i.e., GSTT1 null, GSTM1 null, GSTP1 AB/BB). The 
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association of n-6 PUFAs with colorectal cancer could also be different for those who possessed 
high activity GST genotypes from those who possessed low activity GST genotypes: an inverse 
association would be shown among those who possessed high activity GST genotypes, as the 
harmful products of n-6 PUFAs could be eliminated by GST enzymes. No previous studies have 
investigated the possible interplay between marine n-3 PUFAs and GSTs (i.e., GSTM1, GSTT1 
and GSTP1) for colorectal cancer.  
This potential modification of the marine n-3 PUFAs-colorectal cancer risk association 
by GST genotype warrants investigation. The proposed analyses in the Singapore Chinese Health 
Study will not only help explain the inconsistent results from previous studies investigating the 
association between marine n-3 PUFAs and colorectal cancer, but also provide insight into the 
influence of n-3 PUFA metabolism that could be translated into dietary prevention strategies. In 
summary, it is hypothesized that individuals with high GST enzymatic activity are protected 
against the harmful effects of the lipid peroxidation products.  In other words, higher dietary 
intake of n-3 or n-6 PUFAs may be more beneficial or less harmful, respectively, among 
individuals with high activity than those with low enzymatic activity. In addition, the 
inconsistent results found in epidemiological studies regarding the association of marine n-3 
PUFAs and colorectal cancer may be due to the unaccounted heterogeneity in the enzymatic 
activity of GSTs in the study population. 
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2.0  METHOD 
2.1 STUDY POPULATION 
A nested case-control study was designed within the Singapore Chinese Health Study. 
The details of the Singapore Chinese Health Study, a prospective population-based cohort, have 
been described in detail elsewhere.103 Briefly, the Singapore Chinese Health Study enrolled 
63,257 Chinese women and men between 45 and 74 years of age who were permanent residents 
or citizens of Singapore who reside in government-build housing estates (~86% of Singaporeans 
resided in such facilities at the time) from April 1993 to December 1998.  The study participants 
were drawn from the two major dialect groups of Chinese in Singapore, Hokkien and Cantonese. 
At enrollment baseline interviews were conducted by trained interviewers with a structural 
questionnaire in subjects’ homes. Information on demographics, use of tobacco, physical 
activity, medical history as well as diet was collected.  
The selection process of noncases from the entire cohort was shown in Figure 3. Between 
April 1994 and December 1999, approximately 3% cohort participants were selected randomly, 
and were asked to give blood and single-void urine specimens. Biospecimen collection and 
storage procedure have been described in detail previously.99,104 For those who refused to give 
blood sample, buccal cells were an option. Totally, 1,194 subjects gave their specimens. Of these 
subjects, 27 subjects who had a history of colorectal cancer at recruitment (n=5) or developed 
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first colorectal cancer (n=22) by December 31, 2005 were excluded from the noncases. The 
remaining 1,167 subjects were included as noncases in this study. 
We identified incident colorectal cancer cases through the nationwide cancer registry105.  
As of December 31, 2005, 1,005 colorectal cancer cases had occurred among the cohort 
participants.  Among the 480 cases that provided either blood or buccal samples the following 
were excluded from this study: those with adeno-/carcinoma in situ (n=4), carcinoid tumors 
(n=5) or borderline malignancy (n=2). Of the 469 colorectal cancer cases included in the 
analysis, 271 were located in the colon (C180-189) and 198 were in the rectal/rectosigmoid 
junction (C199 and C209). Stage at diagnosis was available for 92% of cases, where localized 
disease was defined as having either Dukes A (n=67) or B (n=142), and advanced disease was 
either Dukes C (n=141) or D (n=81).  
2.2 EXPOSURE ASSESSMENT 
2.2.1 Dietary assessment 
Dietary information was obtained using a 165-item food frequency questionnaire (FFQ) 
that was developed for, and validated in the study population, as previously described.106 The 
FFQ collected the average frequency and quantity of consuming each food item during last year. 
The FFQ included 14 seafood items commonly consumed by Chinese in Singapore, including 
fresh fish (fish ball or cake, deep fried fish, pan or stir fried fish, boiled or steamed fish), fresh 
shellfish (shrimp or prawn, squid or cuttlefish), dried/salted fish (salted fish, ikan bilis, dried fish, 
other dried seafoods such as dried shrimp, dried oyster, dried cuttlefish) and canned fish (canned 
tuna, canned sardine). Fatty acid composition was computed via linkage to the Singapore Food 
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Composition Database.106 The FFQ was validated using 2 x 24-hour dietary recalls from a 
random sample of 858 cohort participants during April 1994-March 1997. For each dietary 
component, the correlation coefficient and linear regression slope between the food frequency 
and 24-hour recall intakes for subjects within each of the four gender-dialect subgroups were 
calculated according to the method described by Willett and associates.107 The correlation 
coefficients between FFQ- and 24-h recall-based intakes for energy-adjusted total fat intake for 
Cantonese men, Cantonese women, Hokkien men, and Hokkien women were 0.44, 0.47, 0.41, 
and 0.34, respectively.106 
2.2.2 GSTM1, GSTT1, and GSTP1 genotype 
Genomic DNA was isolated using a PureGene Blood Kit (Gentra Systems, Minneapolis, 
MN) or a QIAamp 96 DNA Blood Kit (Qiagen, Valencia, CA). Genotyping for GSTM1, GSTT1 
and GSTP1 was performed using the fluoro-genic 5’-nuclease assay (TaqMan Assay).108 The 
TaqMan assays were performed using a TaqMan PCR Core Reagent kit (Applied Biosystems, 
Foster City, CA) according to the manufacturer’s instructions.  
 The oligonucleotide primers for amplification of the polymorphic region of GSTP1 were 
GC070 for (5’-CCTGGTGGACATGGTGAATG-3’) and GC070 rev (5’-
TGCTCACACCATAGTTGGTGTAGATGA-3’). In addition, the fluorogenic MGB 
oligonucleotide probes used to detect each of the alleles were GC070F (5’-
TGCAAATACGTCTCCCT-3’) labeled with 6-FAM and GC070V 
(5’-TGCAAATACATCTCCCT-3’) labeled with VIC (Applied Biosystems). PCR amplification 
using ~10 ng of genomic DNA was performed in a thermal cycler (MWG Biotech, High Point, 
NC) with an initial step of 95ºC for 10 min followed by 50 cycles of 95ºC for 25 s and 60ºC for 1 
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min. The fluorescence profile of each well was measured in an ABI 7900HT Sequence Detection 
System (Applied Biosystems) and the results analyzed with Sequence Detection Software 
(Applied Biosystems). Experimental samples were compared with 12 controls to identify the 
three genotypes at each locus. Any samples that were outside the parameters defined by the 
controls were identified as non-informative and were retested.  
Genotyping of the GSTT1 and GSTM1 loci consisted of separate assays for GSTT1, 
GSTM1 and the albumin (ALB) control gene. The oligonucleotide primers for amplification of 
the GSTT1, GSTM1 and ALB genes were GC003for (5’-GTGCAAACACCTCCTGGAGAT-3’) 
and GC003rev (5’-AGTCCTTGGCCTTCAGAATGA-3’), GC004for (5’-
CTTGGAGGAACTCCCTGAAAAG-3’) and GC004rev (5’-
TGGAACCTCCATAACACGTGA-3’), GC005for (5’-CGATTTTCTTTTTAGGGCAGTAGC-
3’) and GC005rev (5’-TGGAAACTTCTGCAAACTCAGC-3’), respectively. Fluorescent 
oligonucleotide probes, for detection of PCR reaction products, were synthesized to contain the 
dye 6-FAM (BioSearch Technologies, Novato, CA). The probes for the GSTT1, GSTM1 and 
ALB genes were GC003FAM (5’-ATGCTGCCCATCCCTGCCC-3’), GC004FAM (5’-
AAGCGGCCATGGTTTGCAGG-3’) and GC005FAM (5’-
CGCCTGAGCCAGAGATTTCCCA-3’), respectively. PCR amplification using ~10 ng of 
genomic DNA was performed in an ABI 7900HT Sequence Detection System (Applied 
Biosystems) with an initial step of 95ºC for 10 min followed by 50 cycles of 95ºC for 25s and 
60ºC for 1 min. The fluorescence profile of each well was measured in real-time during the PCR 
amplification and the results analyzed with Sequence Detection Software (Applied Biosystems). 
Any sample with a fluorescence signal that crossed a threshold of 0.2 ΔRn before cycle 40 was 
considered positive for the loci analyzed. Samples negative for both GSTT1 and GSTM1 must be 
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positive for ALB to be called; otherwise, the sample was designated non-informative and 
retested. All analyses were carried out by laboratory personnel who were blinded to the case-
control status of the specimens. 
2.3 STATISTICAL ANALYSIS 
An unconditional logistic regression model was used to obtain odds ratio (ORs) and 
corresponding 95% confidence intervals (CIs) for associations of dietary PUFAs and GST 
genotypes with colorectal cancer. PUFA intake was adjusted for energy intake using the residual 
method.107 Study participants were grouped into quartiles of PUFA intake based on the 
distribution among the entire cohort. P values for trend were determined using ordinal values of 
the quartiles (0, 1, 2, 3).  
The following covariates were individually assessed as  potential confounders: sex, age at 
interview (yr), interview year (1993-1995, 1996-1998), dialect group (Cantonese, Hokkien), 
BMI (<20, 20-23.9, 24-27.9, ≥28 kg2/m)15, education (no formal education, primary level, and  
secondary level or higher), family history of colorectal cancer (yes first degree relative, no), 
diabetes at baseline (yes, no), smoking (never, <13 cigarette/day or started smoking at age of 15 
or older, ≥13 cigarette/day and started smoking at age younger than 15)9, alcohol consumption 
(never, <7 drinks per week, ≥7 drinks per week)9, and weekly vigorous work or strenuous sports 
(yes, no)29.  For each covariate, associations were evaluated with marine n-3 PUFAs (quartile 
variable) using chi-square test (p-value<0.05), and with colorectal cancer using unadjusted 
logistic regression (p-value of any category of a covariate<0.05). Smoking (never, <13 
cigarette/day or started smoking at age of 15 or older, ≥13 cigarette/day and started smoking at 
22 
 
age younger than 15) and alcohol consumption (never, <7 drinks per week, ≥7 drinks per week) 
were statistically significantly associated with colorectal cancer risk. Female gender and BMI 
(<20, 20-23.9, 24-27.9, ≥28 kg2/m) had statistically significant associations with marine n-3 
PUFAs intake. Additional covariates were included in the final models, because their 
relationship with colorectal cancer risk has been previously described in the Singapore cohort, or 
based on a review of the literature.  Therefore, all covariates listed above were included in all 
logistic regression models. 
 Considering the potential overlap in GST enzyme function, two variables were created to 
represent the composite GST profiles to assess their combined effect modification on the 
association between marine n-3 PUFAs and colorectal cancer risk. GSTM1 and GSTT1 genotype 
variables were categorized as null or positive. GSTP1 genotype variables were categorized as 
AB/BB for “low activity” and AA for “high activity”.  
To evaluate effect modification of PUFA-colorectal cancer associations by GST 
genotypes, stratified analyses were conducted by individual GST genotypes (i.e., GSTT1, 
GSTM1, and GSTP1), and by the number of null/low activity alleles. The potential GST-PUFAs 
interaction was tested on a multiplicative scale using models that included a GST-PUFA product 
term, the corresponding GST and PUFA variables, in addition to the covariates included in the 
main model. Gender was also evaluated as a potential effect modifier of the PUFA-colorectal 
cancer associations.   
All colorectal cancer analyses were repeated by subsite for colon and rectum, separately, 
and by stage at diagnosis (i.e., localized vs. advanced). Statistical analysis was conducted with 
the SAS software version 9.3 (SAS Institute, Cary, NC). All p values were two-sided. 
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3.0  RESULTS 
Compared with noncases, colorectal cancer cases were older (percentage of 45-54: 22.2% 
versus 46.3%) and more likely to be male (58.5% versus 43.3%). The distribution of BMI and 
education level was similar among cases and noncases (Table 2). More cases had a positive 
family history of colorectal cancer and diabetes at baseline than noncases. Heavy smokers had a 
3-fold higher risk of colorectal cancer compared with never smokers, and alcohol consumption 
(7 or more drinks per week versus none) was also associated with a statistically significant 
increased risk.   
 There were no differences by increasing level of marine n-3 PUFA intake for age, 
education level, or smoking (Table 3). However, lower intake of marine n-3 PUFAs was seen for 
males, for lower BMI, for having diabetes versus no diabetes history, for drinkers versus 
nondrinkers, and for more frequent physical activity versus none. The dietary intake of most 
foods and nutrients increased with increasing marine n-3 PUFAs intake. 
The prevalence of GSTM1 positive, GSTT1 positive, and GSTP1 AA genotypes among 
noncases was 55%, 59%, and 66%, respectively (Table 4). There was no association between 
GSTT1 or GSTM1 genotype and colorectal cancer risk. There was a trending positive association 
with GSTP1 AA versus AB/BB genotype, but it did not reach statistical significance. Neither the 
number of combined null genotypes in GSTT1 and GSTM1, nor the number of combined 
null/low activity genotypes in GSTT1, GSTM1, and GSTP1 were associated with colorectal 
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cancer risk. No association was observed for colon or rectal cancer risk with individual or 
combined GST genotypes (Table S1). 
For colorectal cancer risk, there was a positive association and statistically significant 
trend with increasing quartiles of the marine n-3 to n-6 PUFA ratio (Table 5). The association for 
highest versus lowest quartile strengthened and became statistically significant for rectal cancer 
risk. The ORs (95% CIs) of colorectal cancer for 2nd, 3rd, and 4th versus 1st quartile were 1.28 
(0.92, 1.78), 1.58 (1.14, 2.20), 1.40 (1.00, 2.00) (p for trend = 0.03). By stage at diagnosis, the 
positive association of the marine n-3 to n-6 PUFA ratio with colorectal cancer was only shown 
for advanced-stage colorectal cancer (Table S2). No associations were observed for colorectal, 
colon or rectal cancer risk with total PUFAs, n-6 PUFAs, n-3 PUFAs, or marine n-3 PUFAs.  
There were also no associations for PUFAs-colorectal cancer risk in analyses among men (Table 
S3). Among women, a statistically significant trend with increasing the ratio of marine n-3 to n-6 
PUFA and colorectal cancer was observed (p for trend < 0.05) (Table S4).  
Stratified analyses by GSTT1 and GSTM1genotypes for dietary PUFAs and colorectal 
cancer risk are shown in Table 6. A statistically significant positive association and trend was 
observed for marine n-3 to n-6 PUFA ratio among GSTT1 null genotype, but not among GSTT1 
positive genotype (p for interaction = 0.02). Similarly, a statistically significant trend with 
marine n-3 to n-6 PUFA ratio was only observed among GSTT1 positive genotype (p for trend = 
0.04). A statistically significant trend with increasing marine n-3 PUFA and colorectal cancer 
risk was observed only among GSTM1 null genotype (p for interaction = 0.02). GSTT1, and 
GSTM1 genotypes did not modify relationships between the other PUFA intake and colorectal 
cancer risk. By subsite, GSTM1 genotype modified the association of total PUFAs, n-6 PUFAs, 
and n-3 PUFAs with colon cancer, but not rectal cancer (Table S5). GSTT1 modified the 
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association of the ratio of marine n-3 to n-6 PUFAs with rectal cancer. In terms of GSTP1, a 
positive association was observed for marine n-3 PUFAs and colorectal cancer risk among 
GSTP1 AA (high activity) genotype (OR for highest versus lowest quartile = 1.39; 95% CI: 0.95, 
2.04; p for trend = 0.04; p for interaction = 0.03) (Table S6). GSTP1 genotype did not modify 
relationships between the other PUFA intake and colorectal cancer risk. By subsite, GSTP1 
genotype modified the association of n-3 PUFAs as well as marine n-3 PUFAs with colon 
cancer, but not rectal cancer. 
To further explore the potential modification by GST genotypes on the marine n-3 PUFA 
and the marine n-3 to n-6 PUFA ratio associations with colorectal cancer, we combined GSTT1 
and GSTM1 genotypes into two categories [i.e., 0 null genotypes and ≥ 1 genotype(s)] (Table 7).  
Inverse associations were observed with marine n-3 PUFA intake and colorectal cancer risk, 
depending on the combined number of GSTT1 and GSTM1 null genotypes.  For marine n-3 
PUFAs, a positive association was observed among those with one or more null GST genotypes, 
while a statistically significant inverse association was observed among those with zero null GST 
genotypes (p for interaction < 0.01).  For the ratio of marine n-3 to n-6 PUFAs, a statistically 
positive association was observed among those with one or more null GST genotypes, and no 
association among those with zero null GST genotypes (p for interaction < 0.01). The 
relationships between marine n-3 PUFAs and marine n-3 to n-6 PUFA ratio with colorectal 
cancer risk by GST genotype were clearest for localized disease (Table 8).
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4.0  DISCUSSIONS 
Using data from the prospective Singapore Chinese Health Study, we conducted a nested 
case-control study to evaluate the potential modifying effects of GST genotypes on the dietary 
PUFAs-colorectal cancer risk association. The main findings include statistically significant 
interaction between marine n-3 PUFA intake and combined GSTT1 and GSTM1 genotype on 
colorectal cancer risk. A trend of increasing risk with marine n-3 PUFA intake was observed 
among those with one or more GST null genotypes, while a trend of decreasing risk was 
observed among those with GST positive genotypes. Similarly, a statistically significant 
association with marine n-3/n-6 PUFAs and colorectal cancer risk was only present among those 
with one or more GST null genotypes. Our findings support a modifying role for combined 
GSTM1 and GSTT1 genotypes on the relationship between marine n-3 PUFAs and colorectal 
cancer risk.  
The association between marine n-3 PUFAs and colorectal cancer has been investigated 
in the U.S.41,48,68,79,80, Finland49, Singapore71, and Japan72. Null findings have been reported for 
U.S.48,68,79 as well as Finland49 population. However, another two studies of U.S. population41,80 
and one study of Japanese72 showed an inverse association between marine n-3 PUFAs and 
colorectal cancer. Our previous study among the Singapore Chinese found a positive association 
between marine n-3 PUFAs and colorectal cancer (OR Q4 vs. Q1 = 1.22, 95% CI = 1.02-1.45, p 
for trend = 0.03).71  
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The role of marine n-3 PUFAs in colorectal cancer development is inconclusive. The 
potential protective effect of marine n-3 PUFAs (i.e., EPA and DHA) on colorectal cancer 
development is based on the inhibiting effect of the marine n-3 PUFAs on COX-2 expression. 
COX-2 metabolizes the n-6 PUFA arachidonic acid into downstream pro-inflammatory 
eicosanoids with established relevance for colorectal carcinogenesis.83 However, it is possible for 
marine n-3 PUFAs having an adverse effect. Marine n-3 PUFAs undergo oxidation and generate 
lipid peroxidation products, MDA and 4-HHE.109 MDA has a high affinity for DNA and the 
resulting 86 MDA-DNA adducts may play a role in the development of colorectal cancer.110 4-
HHE demonstrates carcinogenic potential in vitro by inducing DNA double-strand breaks.88   
Glutathione-associated metabolism is one important pathway in human body to 
metabolize these lipid peroxidation products, and other chemicals related to colorectal 
carcinogenesis.86,101,102 GST gene polymorphisms have been suggested modifying the cigarette 
smoking-colorectal cancer risk association92, and the association with ITCs from cruciferous 
vegetable for colorectal cancer risk99. The effect modification of GST genotypes on the marine 
n-3 PUFAs-colorectal cancer risk association has been less investigated. One study in the 
Netherlands showed that GSTM1 genotype modified the association with fish consumption for 
colorectal cancer. This nested case-control study of 102 cases and 537 controls was conducted 
among Dutch population aged 20-59 years at baseline. Dietary information was collected using a 
FFQ at baseline. Cases were identified via the Netherlands Cancer Registry during an 11-year 
follow-up. An inverse association between fish consumption and colorectal cancer was observed 
among GSTM1 positive. Among GSTM1 positive, those who having fish >4 times per month had 
a 50% lower risk of colorectal cancer [OR > 4 times vs. ≤ 1 time per month = 0.5 (95% CI = 0.2-
1.1)] compared with people consuming fish ≤ 1 time per month. Our findings for an inverse 
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association between marine n-3 PUFAs and colorectal cancer among those with combined 
GSTT1 and GSTM1 positive genotypes were consistent with their results, since fish consumption 
is the source of marine n-3 PUFAs. 
We observed that marine n-3 PUFAs and the ratio of marine n-3 to n-6 PUFAs intake 
was positively associated with colorectal cancer risk among those with one or more GSTT1 and 
GSTM1 null genotypes. This finding is consistent with our previous finding for a positive 
association with marine n-3 PUFAs for colorectal cancer among people possessing the PARP 
codon 762 Ala allele (i.e., carriers of a PARP protein with reduced enzymatic activity).90 PARP 
is a key enzyme involved in repairing lipid hydroperoxide-induced oxidative DNA base 
modifications and single-strand breaks. Together, our findings in the present study for interaction 
between marine n-3 PUFAs and GST genotype, and our previous finding for interaction with 
marine n-3 PUFAs and PARP genotype suggest that higher intake of marine n-3 PUFAs  
increases risk for colorectal cancer among individuals with reduced ability to eliminate lipid 
peroxidation products or repairing lipid hydroperoxide-induced oxidative DNA damage. In 
summary, these findings support the role of lipid peroxidation in explaining the observed 
associations between marine n-3 PUFAs and colorectal cancer risk. 
Strengths of our study include the use of an FFQ and a food composition database that 
were developed for the population, and the validation of FFQ showed a good correlation between 
FFQ- and 24-hr recall fat intake levels.106 The Singapore nationwide cancer registry has been in 
place since 1968 and has been shown to be comprehensive in its recording of cancer cases.111 
Therefore, cancer case ascertainment was complete. There are some limitations. First, the small 
number of cases in this nested case-control study while assessing modification of fatty acid-
colon/rectal cancer association by GST genotypes resulted in rather imprecise estimates. Second, 
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recall bias may exist, since the dietary and covariate information relies on self-reported data. 
This nondifferential misclassification of exposure could result in bias toward or away from the 
null. 
Our study shows that GSTM1 and GSTT1 genotypes modify the association between 
dietary marine n-3 PUFAs and colorectal cancer risk. It suggests that unmeasured genetic 
susceptibility could be a possible explanation of the overall null association between marine n-3 
PUFAs and colorectal cancer among epidemiologic studies, and indirectly support the role of 
lipid peroxidation products in the colorectal carcinogenesis. However, more research is 
necessary to confirm the interaction between GST genotypes and PUFAs on colorectal cancer 
risk. First, given that people having different DNA repair ability determined by DNA repair 
gene, it needs further studied if the interaction between GST genotypes and PUFAs is different 
according to DNA repair gene, such as PARP genotype. Second, more biological research is 
needed to investigate the key role of lipid peroxidation products in the development of colorectal 
cancer, and the relationship between serum level of lipid peroxidation products and GST 
expression. In conclusion, our study shows that GSTT1 and GSTM1 genotypes modify the 
association between marine n-3 PUFAs and colorectal cancer. This effect modification could be 
due to the role of GST enzymes in eliminating lipid peroxidation products.  
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5.0  PUBLIC HEALTH SIGNIFICANCE 
The effect of marine n-3 PUFAs on colorectal cancer has been investigated by many 
studies. Although the potential beneficial effect was found by in vivo and in vitro experiments, 
epidemiological studies did not support this association. Our results supported the role of GST 
genotypes in marine n-3 PUFAs-colorectal cancer association. This finding indirectly suggested 
the importance of lipid peroxidation process in the effect of marine n-3 PUFAs on colorectal 
cancer. This thesis provided evidence that GST genotypes contribute to understanding the 
association between marine n-3 PUFAs and colorectal cancer risk.
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Table 1. Characteristics and results of epidemiologic studies investigating the association between dietary n-3 PUFAs and colorectal cancer riska 
 
Reference Study name Population Age at baseline Country 
Study 
design 
Mean 
Follow-
up 
period 
Exposureb Range Exposure assessment 
Outcome 
(n) 
RR 
(95% 
CI) 
P for 
trend 
Bostick 
(1994)44 
Iowa Women's 
Health Study F 55-60 US cohort 4 years 
Total n-3 
PUFAs 
(g/d) 
>0.18  
vs. 
<0.03 
FFQ 
Colon 
cancer 
(212) 
0.70 
(0.45, 
1.09) 
0.26 
Terry 
(2001)81 
The Swedish 
Mammography 
Screening 
Cohort 
F 40-74 Sweden cohort 9.6 years 
Dietary 
EPA (g/d) 
0.09  
vs. 0.03 FFQ 
Colorectal 
cancer 
(460) 
0.96 
(0.72, 
1.28) 
0.91 
F     Dietary DHA 
0.18  
vs. 0.08   
0.90 
(0.67, 
1.20) 
0.49 
Murff 
(2009)69 
Shanghai 
Women's Health 
Study 
F 40-70 China cohort 11 years Total n-3 PUFA (g/d) 
1.61  
vs. 0.64 FFQ 
Colorectal 
cancer 
(396) 
1.41 
(0.77, 
2.57) 
0.37 
Pietinen 
(1999)49 
Alpha-
Tocopherol, 
Beta-Carotene 
Cancer 
Prevention 
Study 
Male 
smokers 50-69 Finland cohort 8 years 
Marine n-3 
PUFAs 
(g/d) 
0.7  
vs. 0.2 FFQ 
Colorectal 
cancer 
(185) 
1.2 
(0.8, 
1.9) 
0.84 
Hall 
(2008)41 
Physicians' 
Health Study M 43-63 US cohort 22 years 
Marine n-3 
PUFAs 
intake (g/d) 
Q4 vs. 
Q1 
(0.474-
0.048) c 
FFQ 
Colorectal 
cancer 
(500) 
0.76 
(0.59, 
0.98) 
0.02 
Butler 
(2009)71 
Singapore 
Chinese Health 
Study 
M & F 45-74 Singapore cohort 9.8 years 
Marine n-3 
PUFAs 
(g/1000 
kcal) 
0.29  
vs. 0.09 FFQ 
Colorectal 
cancer 
(961) 
1.22 
(1.02, 
1.45) 
0.03 
Daniel 
(2009)48 
Cancer 
Prevenion 
Study-II 
Nutrition 
Cohort 
M 68-70 US cohort 6 years 
Marine n-3 
PUFAs 
intake (g/d) 
≥0.25  
vs. 
<0.10 
FFQ 
Colorectal 
cancer 
(452) 
1.00 
(0.75, 
1.33) 
0.9 
F      
≥0.24  
vs. 
<0.10 
 
Colorectal 
cancer 
(417) 
0.94 
(0.72, 
1.24) 
0.83 
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Table 1 (continued) 
 
Reference Study name Population Age at baseline Country 
Study 
design 
Mean 
Follow-
up 
period 
Exposureb Range Exposure assessment 
Outcome 
(n) 
RR 
(95% 
CI) 
P for 
trend 
Sasazuki 
(2010)72 
Japan Public 
Health Center-
Based 
prospective 
study 
M 40-69 Japan cohort 9.3 years 
Marine n-3 
PUFAs 
(g/d) 
2.18 
 vs. 
0.49 
FFQ 
colorectal 
cancer 
(521) 
0.96 
(0.57, 
1.61) 
0.82 
F      1.92  vs. 0.42  
colorectal 
cancer 
(253) 
0.60 
(0.31, 
1.14) 
0.04 
Kantor 
(2014)79 
VITamins And 
Lifestyle cohort M & F 50-76 US cohort 
6-8 
years 
Dietary 
EPA+DHA 
(g/d) 
≥0.29  
vs. 
<0.08 
FFQ 
Colorectal 
cancer 
(488) 
0.92 
(0.68, 
1.24) 
0.61 
Song 
(2014)68 
Nurses' Health 
Study F 38-63 US cohort 25 years 
Marine n-3 
PUFAs 
(g/day) 
≥0.30  
vs. 
<0.15 
FFQ 
Colorectal 
cancer 
(1469) 
1.03 
(0.89, 
1.20) 
0.68 
Health 
Professionals 
Follow-up 
Study 
M 40-75 US cohort 25 years 
Marine n-3 
PUFAs 
(g/d) 
≥0.41  
vs. 
<0.16 
FFQ 
Colorectal 
cancer 
(987) 
1.05 
(0.85, 
1.30) 
0.82 
Nkondjock 
(2003)112 n/a M & F 35-79 Canada 
case-
control n/a 
Total n-3 
PUFAs 
(g/d) 
>2.92 
vs. 
<1.46 
FFQ 
Colorectal 
cancer 
(402) 
0.73 
(0.51, 
1.05) 
0.017 
Kraja 
(2015)77 
The Rotterdam 
Study M 55- 
The 
Netherlands cohort 
14.6 
years 
Total n-3 
PUFAs 
(g/d) 
1.5 vs. 
0.7 FFQ 
Colorectal 
cancer 
(222) 
1.44 
(1.02, 
2.04) 
0.04 
Kim 
(2010)80 
North Carolina 
Colon Cancer 
Study II 
M & F 40-80 US case-control n/a 
Total n-3 
PUFAs 
(g/d) 
≥2.31  
vs. 
<1.27 
FFQ 
Distal 
large 
bowel 
cancer 
(716) 
0.96 
(0.61, 
1.51) 
0.86 
a Studies were identified using the snowball strategy in an effort to include all published studies as of 02/01/2016.  
b If both of total and marine n-3 PUFAs were presented, marine n-3 PUFAs was selected. 
c For the values which were not provided by the publication, the range was found in other publications using the same data.113
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Table 2. Association of baseline characteristics with colorectal cancer 
 
Baseline characteristics Cases [n (%)] Noncases [n (%)] ORa (95% CI) P valueb 
Age (years), n     0.17 
  45-54 104 (22.2) 540 (46.3) 1.00 (reference)  
  55-64 191 (40.7) 393 (33.7) 1.45 (0.90, 2.34)  
  ≥65 174 (37.1) 234 (20.1) 1.40 (0.63, 3.12)  
Sex, n     <0.01 
  Men 272 (58.0) 506 (43.4) 1.00 (reference)  
  Women 197 (42.0) 661 (56.6) 0.60 (0.48, 0.75)  
BMI (kg/m2), n    0.11 
  <20 77 (16.4) 186 (15.9) 1.00 (reference)  
  20-23.9 243 (51.8) 651 (55.8) 0.82 (0.60, 1.13)  
  24-27.9 118 (25.2) 268 (23.0) 1.04 (0.73, 1.49)  
  ≥28 31 (6.6) 62 (5.3) 1.32 (0.78, 2.25)  
Education  level, n    0.19 
  No formal education 129 (27.5) 313 (26.8) 1.00 (reference)  
  Primary level 232 (49.5) 502 (43.0) 1.24 (0.92, 1.66)  
  Secondary level or higher 108 (23.0) 352 (30.2) 1.00 (0.71, 1.42)  
Family history, n    <0.01 
  No 447 (95.3) 1139 (97.6) 1.00 (reference)  
  Yes 22 (4.7) 28 (2.4) 2.32 (1.27, 4.23)  
Diabetes at baseline, n    0.12 
  No 403 (85.9) 1058 (90.7) 1.00 (reference)  
  Yes 66 (14.1) 109 (9.3) 1.31 (0.93, 1.84)  
Smoking, n    <0.01 
  Never 271 (57.8) 845 (72.4) 1.00 (reference)  
  <13 cigarette/day or started smoking at age 15 or older 158 (33.7) 292 (25.0) 1.12 (0.85, 1.49)  
  ≥13 cigarette/day and started smoking before age 15 40 (8.5) 30 (2.6) 3.09 (1.82, 5.25)  
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Table 2 (continued) 
 
Baseline characteristics Cases [n (%)] Noncases [n (%)] ORa (95% CI) P valueb 
Alcohol, n    0.02 
  Never 361 (77.0) 957 (82.0) 1.00 (reference)  
  <7 drinks per week 70 (14.9) 164 (14.1) 1.06 (0.77, 1.48)  
  ≥7 drinks per week 38 (8.1) 46 (3.9) 2.01 (1.25, 3.24)  
Weekly vigorous work or strenuous sports, n    0.96 
  No 424 (90.4) 1021 (87.5) 1.00 (reference)  
  Yes 45 (9.6) 146 (12.5) 0.99 (0.68, 1.45)  
Abbreviations: Body mass index (BMI), Confidence interval (CI), Odds ratio (OR). 
a Unconditional logistic regression models were adjusted for sex, age at interview, interview year, and dialect group.  
b From Wald Test
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Table 3. Distribution of baseline characteristics according to quartile (Q) intake of marine n-3 PUFAs among noncases (n=1,167) 
 
 Marine n-3 PUFAs, g/1000kcal p valueb Baseline characteristics Q1a Q2 Q3 Q4 
  Mean age in year (SD) 57.1 (8.0) 56.1 (8.4) 56.5 (7.8) 56.2 (8.0) 0.407 
  Sex, % men 48.6 44.4 44.3 36.3 0.026 
  Mean BMI in kg/m2 (SD) 22.4 (3.0) 22.7 (3.1) 22.9 (3.0) 23.5 (3.2) <0.001 
  Education level, % no formal education 25.7 24.9 24.8 31.9 0.144 
  Diabetes at baseline, % yes 7.9 9.4 8.7 11.3 0.534 
  Smoking index, % never smoker 70.7 72.1 74.5 72.3 0.245 
  Alcohol, % nondrinker 79.3 79.5 81.5 87.7 0.030 
  Weekly vigorous work or strenuous sports, % yes 15.7 14.1 12.8 7.5 0.019 
Mean daily intake (SD)      
  Total energy, kcal 1557.6 (515.6) 1620.3 (561.0) 1577.5 (519.7) 1466.3 (530.1) <0.001 
  Vegetables, g 96.3 (55.9) 111.3 (58.4) 115.7 (60.4) 119.1 (70.0) <0.001 
  Fruits, g 198.8 (157.5) 223.4 (166.0) 214.4 (169.0) 195.2 (169.4) 0.080 
  Red meat, g 24.4 (23.4) 32.7 (28.4) 32.8 (22.4) 32.5 (28.2) <0.001 
  Fish, g 26.0 (13.1) 47.7 (17.5) 61.9 (20.8) 83.7 (29.6) <0.001 
  Folate, µg/1000kcal 96.4(32.4) 101.0 (30.7) 103.6 (32.2) 104.2 (32.2) 0.010 
  Calcium, mg/1000kcal 262.4 (134.7) 277.3 (135.5) 279.9 (126.8) 283.3 (119.3) 0.003 
  Fiber, g/1000kcal  8.1 (2.7) 8.5 (2.8) 8.4 (2.7) 8.4 (2.6) 0.290 
  Total fat, g/1000kcal 22.6 (6.2) 25.0 (5.5) 25.8 (4.8) 27.6 (5.5) <0.001 
  Saturated fat, g/1000kcal 8.2 (2.8) 8.9 (2.6) 8.8 (2.3) 9.5 (2.5) <0.001 
  Monounsaturated fat, g/1000kcal 7.7 (2.2) 8.5 (2.0) 8.7 (1.8) 9.3 (2.1) <0.001 
  Total PUFAs, g/1000kcal 4.5 (1.7) 5.0 (1.7) 5.6 (2.0) 5.8 (2.0) <0.001 
    Total n-6 PUFAs, g/1000kcal 4.1 (1.6) 4.5 (1.6) 5.0 (1.9) 5.1 (1.9) <0.001 
    Total n-3 PUFAs, g/1000kcal 0.40 (0.12) 0.49 (0.15) 0.56 (0.18) 0.65 (0.16) <0.001 
      Marine n-3 PUFAs, g/1000kcal 0.08 (0.03) 0.15 (0.02) 0.21 (0.02) 0.31 (0.06) <0.001 
Abbreviations: Body mass index (BMI), Polyunsaturated fatty acids (PUFAs), Standard deviation (SD). 
a Quartiles of marine n-3 PUFAs are based on the distribution of the entire cohort. 
b From χ2 test for categorical variables and Kruskal-Wallis Test for continuous variables. 
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Table 4. Odds ratios and 95% confidence intervals for GST genotype and colorectal cancer risk  
 
 Case/noncase ORa (95% CI) ORb (95% CI) 
GSTT1    
  Null 182/476 1.00 (reference) 1.00 (reference) 
  Positive 287/691 1.09 (0.87, 1.37) 1.08 (0.86, 1.36) 
GSTM1    
  Null 230/526 1.00 (reference) 1.00 (reference) 
  Positive 239/641 0.89 (0.71, 1.12) 0.88 (0.70, 1.11) 
GSTP1    
  AB/BB 135/396 1.00 (reference) 1.00 (reference) 
  AA 334/771 1.22 (0.96, 1.56) 1.23 (0.96, 1.58) 
# of null genotypes in GSTT1 and GSTM1    
  0 150/387 1.00 (reference) 1.00 (reference) 
  1 226/558 1.00 (0.78, 1.29) 0.99 (0.77, 1.28) 
  2 93/222 1.03 (0.75, 1.42) 1.06 (0.77, 1.47) 
# of null or low activity genotypes in GSTT1, GSTM1,GSTP1     
  0 104/263 1.00 (reference) 1.00 (reference) 
  1 205/483 1.06 (0.79, 1.41) 1.03 (0.76, 1.38) 
  2 138/348 0.97 (0.71, 1.33) 0.97 (0.71, 1.34) 
  3 22/73 0.78 (0.45, 1.35) 0.78 (0.45, 1.36) 
Abbreviations: Confidence interval (CI), Glutathione S-transferase (GST), Glutathione S-transferase theta 1 (GSTT1), Glutathione S-
transferase mu 1 (GSTM1), Glutathione S-transferase pi 1 (GSTP1), Odds ratio (OR). 
a Unconditional logistic regression models were adjusted for sex, age at interview, interview year, and dialect group. 
b Unconditional logistic regression models were adjusted for sex, age at interview, interview year, dialect group, body mass index, 
education, family history, diabetes at baseline, smoking, drinking, and physical activity.
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Table 5. Odds ratios and 95% confidence intervals for dietary polyunsaturated fatty acid (PUFA) intake and risk of colorectal, colon and 
rectal cancer 
 Median 
value 
Colorectal cancer  Colon cancer  Rectal cancer 
 Case/ 
noncase OR
a (95% CI)  Case/ noncase OR
a (95% CI)  Case/ noncase OR
a (95% CI) 
Total PUFAs, 
g/day          
  Q1 5.57 116/265 1.00 (reference)  63/265 1.00 (reference)  53/265 1.00 (reference) 
  Q2 7.58 124/296 1.10 (0.80, 1.52)  72/296 1.08 (0.73, 1.60)  52/296 1.06 (0.68, 1.65) 
  Q3 9.14 128/286 1.19 (0.86, 1.66)  80/286 1.25 (0.85, 1.86)  48/286 1.06 (0.67, 1.68) 
  Q4 12.56 101/320 0.86 (0.61, 1.20)  56/320 0.80 (0.53, 1.22)  45/320 0.91 (0.57, 1.45) 
  P for trend    0.47   0.46   0.71 
n-6 PUFAs, g/day          
  Q1 4.88 120/269 1.00 (reference)  64/269 1.00 (reference)  56/269 1.00 (reference) 
  Q2 6.71 112/289 0.96 (0.69, 1.33)  69/289 1.00 (0.67, 1.49)  43/289 0.82 (0.52, 1.30) 
  Q3 8.12 133/288 1.22 (0.88, 1.69)  78/288 1.23 (0.83, 1.82)  55/288 1.17 (0.75, 1.83) 
  Q4 11.30 104/321 0.85 (0.61, 1.18)  60/321 0.83 (0.55, 1.26)  44/321 0.84 (0.53, 1.33) 
  P for trend   0.64   0.61   0.78 
Total n-3 PUFAs, 
g/day          
  Q1 0.62 116/273 1.00 (reference)  71/273 1.00 (reference)  45/273 1.00 (reference) 
  Q2 0.79 115/294 1.02 (0.73, 1.41)  65/294 0.87 (0.59, 1.30)  50/294 1.29 (0.81, 2.06) 
  Q3 0.91 127/289 1.16 (0.84, 1.61)  68/289 0.96 (0.65, 1.42)  59/289 1.55 (0.98, 2.46) 
  Q4 1.14 111/311 0.96 (0.69, 1.33)  67/311 0.88 (0.59, 1.30)  44/311 1.11 (0.69, 1.79) 
  P for trend   0.96   0.63   0.53 
Marine n-3 
PUFAs, g/day           
  Q1 0.16 107/276 1.00 (reference)  65/276 1.00 (reference)  42/276 1.00 (reference) 
  Q2 0.26 109/305 0.90 (0.65, 1.26)  68/305 0.88 (0.60, 1.31)  41/305 0.86 (0.53, 1.39) 
  Q3 0.35 124/285 1.12 (0.81, 1.55)  70/285 1.00 (0.67, 1.48)  54/285 1.28 (0.81, 2.02) 
  Q4 0.48 129/301 1.09 (0.79, 1.50)  68/301 0.92 (0.62, 1.36)  61/301 1.37 (0.87, 2.15) 
  P for trend   0.36   0.84   0.06 
39 
 
Table 5 (continued) 
 
 Median 
value 
Colorectal cancer  Colon cancer  Rectal cancer 
 Case/ 
noncase OR
a (95% CI)  Case/ noncase OR
a (95% CI)  Case/ noncase OR
a (95% CI) 
Marine n-3/n-6 
PUFAs          
  Q1 0.021 91/305 1.00 (reference)  59/305 1.00 (reference)  32/305 1.00 (reference) 
  Q2 0.034 118/322 1.28 (0.92, 1.78)  64/322 1.04 (0.70, 1.55)  54/322 1.72 (1.06, 2.80) 
  Q3 0.047 136/273 1.58 (1.14, 2.20)  82/273 1.43 (0.97, 2.11)  54/273 1.77 (1.08, 2.88) 
  Q4 0.073 124/267 1.40 (1.00, 2.00)  66/267 1.18 (0.78, 1.77)  58/267 1.88 (1.15, 3.06) 
  P for trend   0.03   0.20   0.02 
Abbreviations: Confidence interval (CI), Odds ratio (OR). 
a Unconditional logistic regression models were adjusted for sex, age at interview, interview year, dialect group, body mass index, 
education, family history, diabetes at baseline, smoking, drinking, and physical activity.
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Table 6. Odds ratios and 95% confidence intervals for dietary polyunsaturated fatty acid (PUFA) intake and risk of colorectal cancer by 
GSTT1 and GSTM1 genotype  
 
 GSTT1 null GSTT1 positive  GSTM1 null GSTM1 positive 
 Case/ noncase OR
a (95% CI) Case/ noncase OR
a (95% CI)  Case/ noncase OR
a (95% CI) Case/ noncase OR
a (95% CI) 
Total PUFAs          
  Q1 46/100 1.00 (reference) 70/165 1.00 (reference)  51/126 1.00 (reference) 65/139 1.00 (reference) 
  Q2 54/120 1.10 (0.66, 1.84) 70/176 1.10 (0.72, 1.67)  58/125 1.40 (0.86, 2.30) 66/171 0.94 (0.61, 1.44) 
  Q3 43/130 0.85 (0.49, 1.46) 85/156 1.47 (0.97, 2.23)  67/128 1.65 (1.01, 2.71) 61/158 0.93 (0.59, 1.45) 
  Q4 39/126 0.82 (0.47, 1.43) 62/194 0.89 (0.58, 1.37)  54/147 1.23 (0.74, 2.04) 47/137 0.65 (0.41, 1.04) 
  P for trend  0.32  0.95   0.37  0.09 
  P for interaction    0.26     0.08 
N-6 PUFAs          
  Q1 46/102 1.00 (reference) 74/167 1.00 (reference)  54/128 1.00 (reference) 66/141 1.00 (reference) 
  Q2 58/115 0.97 (0.57, 1.63) 64/174 0.95 (0.62, 1.44)  49/122 1.09 (0.66, 1.80) 63/167 0.88 (0.57, 1.36) 
  Q3 48/126 1.01 (0.59, 1.73) 85/162 1.36 (0.90, 2.06)  69/127 1.71 (1.05, 2.78) 64/161 0.95 (0.61, 1.48) 
  Q4 40/133 0.79 (0.46, 1.38) 64/188 0.89 (0.58, 1.37)  58/149 1.21 (0.74, 1.99) 46/172 0.63 (0.40, 1.01) 
  P for trend  0.46  0.94   0.22  0.09 
  P for interaction    0.32     <0.05 
N-3 PUFAs          
  Q1 40/111 1.00 (reference) 76/162 1.00 (reference)  52/123 1.00 (reference) 64/150 1.00 (reference) 
  Q2 41/121 1.18 (0.68, 2.06) 74/173 0.95 (0.63, 1.44)  55/136 1.10 (0.68, 1.79) 60/158 0.95 (0.61, 1.49) 
  Q3 58/120 1.68 (0.99, 2.87) 69/169 0.92 (0.60, 1.39)  62/127 1.35 (0.83, 2.18) 65/162 1.03 (0.66, 1.60) 
  Q4 43/124 1.27 (0.73, 2.22) 68/187 0.83 (0.55, 1.25)  61/140 1.29 (0.79, 2.09) 50/171 0.72 (0.46, 1.15) 
  P for trend  0.22  0.36   0.23  0.23 
  P for interaction    0.18     0.09 
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Table 6 (continued) 
 
 GSTT1 null GSTT1 positive  GSTM1 null GSTM1 positive 
 Case/ noncase OR
a (95% CI) Case/ noncase OR
a (95% CI)  Case/ noncase OR
a (95% CI) Case/ noncase OR
a (95% CI) 
Marine n-3 PUFAs          
  Q1 35/108 1.00 (reference) 72/168 1.00 (reference)  51/139 1.00 (reference) 56/137 1.00 (reference) 
  Q2 40/122 0.84 (0.48, 1.47) 69/183 0.94 (0.62, 1.41)  51/145 0.92 (0.57, 1.49) 58/160 0.89 (0.56, 1.41) 
  Q3 49/113 1.38 (0.80, 2.39) 75/172 1.01 (0.67, 1.52)  58/111 1.54 (0.95, 2.50) 66/174 0.87 (0.56, 1.35) 
  Q4 58/133 1.28 (0.75, 2.18) 71/168 0.98 (0.65, 1.48)  70/131 1.54 (0.97, 2.46) 59/170 0.78 (0.50, 1.23) 
  P for trend  0.14  1.00   0.02  0.30 
  P for interaction    0.19     0.02 
Marine n-3/n-6 PUFAs          
  Q1 28/116 1.00 (reference) 63/189 1.00 (reference)  49/144 1.00 (reference) 42/161 1.00 (reference) 
  Q2 40/145 1.15 (0.65, 2.06) 78/177 1.41 (0.94, 2.13)  49/149 1.06 (0.65, 1.72) 69/173 1.53 (0.96, 2.42) 
  Q3 61/111 2.06 (1.19, 3.59) 75/162 1.37 (0.90, 2.08)  66/114 1.69 (1.05, 2.73) 70/159 1.53 (0.96, 2.44) 
  Q4 53/104 1.91 (1.08, 3.36) 71/163 1.15 (0.75, 1.77)  66/119 1.46 (0.90, 2.38) 58/148 1.29 (0.80, 2.09) 
  P for trend  <0.01  0.56   0.04  0.36 
  P for interaction    0.02     0.39 
Abbreviations: Confidence interval (CI), Glutathione S-transferase theta 1 (GSTT1), Glutathione S-transferase mu 1 (GSTM1), Odds 
ratio (OR). 
a Unconditional logistic regression models were adjusted for sex, age at interview, interview year, dialect group, body mass index, 
education, family history, diabetes at baseline, smoking, drinking, and physical activity.
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Table 7. Odds ratios and 95% confidence intervals for dietary polyunsaturated fatty acid (PUFA) intake and risk of colorectal cancer by 
number of null genotypes in GSTT1 and GSTM1 
 
 ≥1 0 
 Case/noncase ORa (95% CI) Case/noncase ORa (95% CI) 
Marine n-3 PUFAs     
  Q1 63/196 1.00 (reference) 44/80 1.00 (reference) 
  Q2 73/204 1.03 (0.68, 1.55) 36/101 0.70 (0.40, 1.23) 
  Q3 85/175 1.59 (1.06, 2.39) 39/110 0.62 (0.36, 1.07) 
  Q4 98/205 1.49 (1.00, 2.23) 31/96 0.57 (0.32, 1.01) 
  P for trend  0.01  <0.05 
  P for interaction    <0.01 
Marine n-3/n-6 PUFAs     
  Q1 62/209 1.00 (reference) 29/96 1.00 (reference) 
  Q2 66/217 1.08 (0.71, 1.65) 52/105 1.67 (0.96, 2.93) 
  Q3 97/180 1.73 (1.16, 2.59) 39/93 1.26 (0.70, 2.28) 
  Q4 94/174 1.64 (1.09, 2.37) 30/93 0.94 (0.50, 1.77) 
  P for trend  <0.01  0.58 
  P for interaction    0.01 
Abbreviations: Confidence interval (CI), Glutathione S-transferase theta 1 (GSTT1), Glutathione S-transferase mu 1 (GSTM1), Odds 
ratio (OR). 
a Unconditional logistic regression models were adjusted for sex, age at interview, interview year, dialect group, body mass index, 
education, family history, diabetes at baseline, smoking, drinking, and physical activity.
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Table 8. Odds ratios and 95% confidence intervals for dietary polyunsaturated fatty acid (PUFA) intake and risk of localized and 
advanced colorectal cancer by number of null genotypes in GSTT1 and GSTM1 
 ≥1 0 
 Case/ noncase OR
a (95% CI) Case/ noncase OR
a (95% CI) 
LOCALIZED     
Marine n-3 PUFAs     
  Q1 20/205 1.00 (reference) 24/81 1.00 (reference) 
  Q2 34/208 1.50 (0.81, 2.78) 19/104 0.59 (0.29, 1.20) 
  Q3 38/180 2.26 (1.23, 4.15) 16/114 0.39 (0.19, 0.82) 
  Q4 44/214 2.08 (1.15, 3.78) 14/99 0.40 (0.19, 0.86) 
  P for trend  <0.01  <0.01 
  P for interaction    <0.01 
Marine n-3/n-6 PUFAs     
  Q1 28/215 1.00 (reference) 17/98 1.00 (reference) 
  Q2 22/223 0.81 (0.44, 1.51) 28/107 1.44 (0.72, 2.87) 
  Q3 41/186 1.60 (0.92, 2.78) 19/97 0.89 (0.42, 1.88) 
  Q4 45/183 1.73 (0.99, 3.00) 9/96 0.43 (0.17, 1.07) 
  P for trend  0.01  0.04 
  P for interaction    <0.01 
ADVANCED     
Marine n-3 PUFAs     
  Q1 34/205 1.00 (reference) 19/83 1.00 (reference) 
  Q2 35/208 0.96 (0.56, 1.65) 14/105 0.74 (0.34, 1.61) 
  Q3 42/180 1.53 (0.91, 2.58) 19/114 0.77 (0.37, 1.58) 
  Q4 45/214 1.33 (0.79, 2.22) 14/99 0.64 (0.30, 1.39) 
  P for trend  0.12  0.30 
  P for interaction    0.07 
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Table 8 (continued) 
 
 ≥1 0 
(ADVANCED) Case/ noncase OR
a (95% CI) Case/ noncase OR
a (95% CI) 
Marine n-3/n-6 PUFAs     
  Q1 28/215 1.00 (reference) 10/98 1.00 (reference) 
  Q2 38/223 1.45 (0.84, 2.50) 22/107 2.21 (0.97, 5.02) 
  Q3 50/186 2.05 (1.21, 3.48) 16/97 1.70 (0.71, 4.06) 
  Q4 40/183 1.51 (0.87, 2.63) 18/96 1.81 (0.76, 4.28) 
  P for trend  0.07  0.37 
  P for interaction    0.61 
Abbreviations: Confidence interval (CI), Glutathione S-transferase theta 1 (GSTT1), Glutathione S-transferase mu 1 (GSTM1), Odds 
ratio (OR), Polyunsaturated fatty acids (PUFAs). 
a Unconditional logistic regression models were adjusted for sex, age at interview, interview year, dialect group, body mass index, 
education, family history, diabetes at baseline, smoking, drinking, and physical activity. 
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APPENDIX B: FIGURES
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Figure 167 Metabolism of (n-6) and (n-3) families of PUFA 
 
 
 
 
 
Figure 267 The AA cascade, from LA to PGs 
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Figure 3 The selection process of noncases from the entire cohort 
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Table S1. Odds ratios and 95% confidence intervals for GST genotype and colon and rectal cancer risk 
 
 Colon Cancer  Rectal Cancer 
 Case/noncase ORa (95% CI)  Case/noncase ORa (95% CI) 
GSTT1      
  Null 100/476 1.00 (reference)  82/476 1.00 (reference) 
  Positive 171/691 1.20 (0.90, 1.59)  116/691 0.94 (0.68, 1.30) 
GSTM1      
  Null 138/526 1.00 (reference)  92/526 1.00 (reference) 
  Positive 133/641 0.81 (0.61, 1.07)  106/641 0.96 (0.70, 1.33) 
GSTP1      
  AB/BB 81/396 1.00 (reference)  54/396 1.00 (reference) 
  AA 190/771 1.16 (0.86, 1.57)  144/771 1.35 (0.95, 1.92) 
# of null genotypes in GSTT1 and GSTM1      
  0 87/387 1.00 (reference)  63/387 1.00 (reference) 
  1 130/558 0.99 (0.72, 1.35)  96/558 1.03 (0.72, 1.48) 
  2 54/222 1.05 (0.71, 1.56)  39/222 1.11 (0.70, 1.75) 
# of null or low activity genotypes in GSTT1, GSTM1,GSTP1       
  0 60/263 1.00 (reference)  44/263 1.00 (reference) 
  1 119/483 1.03 (0.72, 1.47)  86/483 1.02 (0.67, 1.55) 
  2 76/348 0.92 (0.63, 1.36)  62/348 1.07 (0.69, 1.67) 
  3 16/73 0.99 (0.53, 1.86)  6/73 0.49 (0.20, 1.25) 
Abbreviations: Confidence interval (CI), Glutathione S-transferase (GST), Glutathione S-transferase theta 1 (GSTT1), Glutathione S-
transferase mu 1 (GSTM1), Glutathione S-transferase pi 1 (GSTP1), Odds ratio (OR). 
a Unconditional logistic regression models were adjusted for sex, age at interview, interview year, dialect group, body mass index, 
education, family history, diabetes at baseline, smoking, drinking, and physical activity. 
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Table S2. Odds ratios and 95% confidence intervals for dietary polyunsaturated fatty acid (PUFA) intake and risk of localized 
and advanced colorectal cancer 
 
 Localized  Advanced 
 Case/noncase ORa (95% CI)  Case/noncase ORa (95% CI) 
Total PUFAs      
  Q1 51/274 1.00 (reference)  56/274 1.00 (reference) 
  Q2 56/306 1.12 (0.72, 1.73)  58/306 1.07 (0.70, 1.62) 
  Q3 59/298 1.22 (0.78, 1.89)  57/298 1.10 (0.72, 1.69) 
  Q4 43/327 0.80 (0.50, 1.27)  51/327 0.92 (0.59, 1.42) 
  P for trend   0.44   0.74 
N-6 PUFAs      
  Q1 53/277 1.00 (reference)  59/277 1.00 (reference) 
  Q2 48/301 0.89 (0.57, 1.40)  52/301 0.88 (0.58, 1.35) 
  Q3 62/299 1.27 (0.82, 1.95)  60/299 1.11 (0.73, 1.69) 
  Q4 46/328 0.81 (0.51, 1.29)  51/328 0.85 (0.55, 1.32) 
  P for trend  0.72   0.72 
Total n-3 PUFAs      
  Q1 51/281 1.00 (reference)  57/281 1.00 (reference) 
  Q2 55/303 1.14 (0.73, 1.76)  51/303 0.96 (0.63, 1.49) 
  Q3 62/297 1.27 (0.83, 1.96)  57/297 1.15 (0.75, 1.76) 
  Q4 41/324 0.76 (0.48, 1.21)  57/324 1.03 (0.68, 1.57) 
  P for trend  0.36   0.72 
Marine n-3 PUFAs       
  Q1 44/286 1.00 (reference)  53/286 1.00 (reference) 
  Q2 53/312 1.03 (0.66, 1.62)  49/312 0.86 (0.56, 1.34) 
  Q3 54/294 1.11 (0.71, 1.74)  61/294 1.18 (0.78, 1.79) 
  Q4 58/313 1.11 (0.71, 1.74)  59/313 1.04 (0.68, 1.58) 
  P for trend  0.59   0.54 
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Table S2 (continued) 
 
 Localized  Advanced 
 Case/noncase ORa (95% CI)  Case/noncase ORa (95% CI) 
Marine n-3/n-6 PUFAs      
  Q1 45/313 1.00 (reference)  38/313 1.00 (reference) 
  Q2 50/330 1.07 (0.68, 1.68)  60/330 1.63 (1.04, 2.55) 
  Q3 60/283 1.32 (0.85, 2.05)  66/283 1.91 (1.23, 2.99) 
  Q4 54/279 1.16 (0.74, 1.83)  58/279 1.60 (1.01, 2.53) 
  P for trend  0.36   0.04 
Abbreviations: Confidence interval (CI), Odds ratio (OR). 
a Unconditional logistic regression models were adjusted for sex, age at interview, interview year, dialect group, body mass index, 
education, family history, diabetes at baseline, smoking, drinking, and physical activity.
52 
 
Table S3. Odds ratios and 95% confidence intervals for dietary polyunsaturated fatty acid (PUFA) intake and risk of 
colorectal, colon and rectal cancer among men  
 Median 
value 
Colorectal cancer Colon cancer Rectal cancer 
 Case/ noncase ORa (95% CI) Case/ noncase ORa (95% CI) Case/ noncase ORa (95% CI) 
Total PUFAs, g/day      
  Q1 5.36 93/158 1.00 (reference) 51/158 1.00 (reference) 42/158 1.00 (reference) 
  Q2 7.62 64/134 0.83 (0.55, 1.26) 30/134 0.66 (0.39, 1.11) 34/134 1.01 (0.59, 1.73) 
  Q3 9.18 58/102 0.88 (0.57, 1.38) 30/102 0.75 (0.43, 1.30) 28/102 1.03 (0.58, 1.85) 
  Q4 13.00 57/112 0.81 (0.52, 1.26) 28/112 0.64 (0.37, 1.12) 29/112 0.97 (0.55, 1.73) 
  P for trend   0.39  0.14  0.95 
N-6 PUFAs, g/day      
  Q1 4.70 95/157 1.00 (reference) 50/157 1.00 (reference) 45/157 1.00 (reference) 
  Q2 6.72 57/136 0.69 (0.45, 1.06) 31/136 0.65 (0.39, 1.11) 26/136 0.67 (0.38, 1.17) 
  Q3 8.12 63/99 0.96 (0.62, 1.49) 29/99 0.75 (0.43, 1.30) 34/99 1.19 (0.68, 2.07) 
  Q4 11.66 57/114 0.76 (0.49, 1.19) 29/114 0.65 (0.37, 1.13) 28/114 0.83 (0.47, 1.48) 
  P for trend   0.41  0.16  0.93 
N-3 PUFAs, g/day      
  Q1 0.59 85/159 1.00 (reference) 49/159 1.00 (reference) 36/159 1.00 (reference) 
  Q2 0.79 63/130 0.90 (0.58, 1.37) 33/130 0.78 (0.46, 1.33) 30/130 1.10 (0.61, 1.96) 
  Q3 0.91 64/99 1.05 (0.67, 1.63) 26/99 0.72 (0.40, 1.27) 38/99 1.53 (0.87, 2.71) 
  Q4 1.18 60/118 0.87 (0.57, 1.35) 31/118 0.74 (0.43, 1.26) 29/118 1.06 (0.59, 1.90) 
  P for trend   0.70  0.23  0.57 
Marine n-3 PUFAs, g/day      
  Q1 0.14 75/140 1.00 (reference) 44/140 1.00 (reference) 31/140 1.00 (reference) 
  Q2 0.26 53/123 0.62 (0.40, 0.98) 26/123 0.49 (0.28, 0.88) 27/123 0.79 (0.43, 1.44) 
  Q3 0.35 63/118 0.80 (0.52, 1.25) 30/118 0.65 (0.37, 1.14) 33/118 1.06 (0.59, 1.89) 
  Q4 0.50 81/125 0.96 (0.63, 1.47) 39/125 0.75 (0.44, 1.27) 42/125 1.26 (0.72, 2.19) 
  P for trend   0.86  0.45  0.26 
Marine n-3/n-6 PUFAs      
  Q1 0.02 59/142 1.00 (reference) 37/142 1.00 (reference) 22/142 1.00 (reference) 
  Q2 0.03 61/119 1.19 (0.76, 1.88) 28/119 0.88 (0.50, 1.56) 33/119 1.73 (0.93, 3.20) 
  Q3 0.05 67/112 1.24 (0.79, 1.95) 29/112 0.87 (0.49, 1.55) 38/112 1.85 (1.01, 3.39) 
  Q4 0.08 85/133 1.32 (0.85, 2.05) 45/133 1.21 (0.70, 2.06) 40/133 1.66 (0.91, 3.04) 
  P for trend   0.22  0.51  0.12 
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Abbreviations: Confidence interval (CI), Odds ratio (OR). 
a Unconditional logistic regression models were adjusted for age at interview, interview year, dialect group, body mass index, 
education, family history, diabetes at baseline, smoking, drinking, and physical activity.
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Table S4. Odds ratios and 95% confidence intervals for dietary polyunsaturated fatty acid (PUFA) intake and risk of 
colorectal, colon and rectal cancer among women 
 Median 
value 
Colorectal cancer Colon cancer Rectal cancer 
 Case/ noncase ORa (95% CI) Case/ noncase ORa (95% CI) Case/ noncase ORa (95% CI) 
Total PUFAs, g/day      
  Q1 5.89 23/107 1.00 (reference) 12/107 1.00 (reference) 11/107 1.00 (reference) 
  Q2 7.55 60/162 1.88 (1.07, 3.31) 42/162 2.46 (1.21, 4.98) 18/162 1.26 (0.55, 2.88) 
  Q3 9.13 70/184 1.96 (1.13, 3.41) 50/184 2.74 (1.37, 5.48) 20/184 1.14 (0.50, 2.59) 
  Q4 12.38 44/208 1.12 (0.63, 2.02) 28/208 1.37 (0.65, 2.88) 16/208 0.92 (0.39, 2.16) 
  P for trend   0.89  0.80  0.70 
N-6 PUFAs, g/day      
  Q1 5.26 25/112 1.00 (reference) 14/112 1.00 (reference) 11/112 1.00 (reference) 
  Q2 6.69 55/153 1.71 (0.98, 2.98) 38/153 2.03 (1.03, 3.99) 17/153 1.33 (0.58, 3.05) 
  Q3 8.12 70/189 1.87 (1.09, 3.21) 49/189 2.36 (1.22, 4.57) 21/189 1.24 (0.55, 2.82) 
  Q4 11.18 47/207 1.13 (0.64, 2.00) 31/207 1.33 (0.66, 2.67) 16/207 0.96 (0.41, 2.25) 
  P for trend   0.92  0.65  0.79 
N-3 PUFAs, g/day      
  Q1 0.65 31/114 1.00 (reference) 22/114 1.00 (reference) 9/114 1.00 (reference) 
  Q2 0.80 52/164 1.17 (0.69, 1.99) 32/164 1.01 (0.55, 1.89) 20/164 1.50 (0.63, 3.60) 
  Q3 0.92 63/190 1.40 (0.84, 2.35) 42/190 1.29 (0.72, 2.34) 21/190 1.79 (0.76, 4.20) 
  Q4 1.13 51/193 1.14 (0.67, 1.95) 36/193 1.13 (0.61, 2.08) 15/193 1.27 (0.51, 3.13) 
  P for trend   0.56  0.53  0.64 
Marine n-3 PUFAs, g/day      
  Q1 0.17 32/136 1.00 (reference) 21/136 1.00 (reference) 11/136 1.00 (reference) 
  Q2 0.27 56/182 1.45 (0.86, 2.42) 42/182 1.57 (0.87, 2.85) 14/182 1.14 (0.48, 2.69) 
  Q3 0.35 61/167 1.76 (1.06, 2.94) 40/167 1.69 (0.93, 3.08) 21/167 1.79 (0.80, 3.99) 
  Q4 0.48 48/176 1.30 (0.77, 2.20) 29/176 1.19 (0.63, 2.24) 19/176 1.53 (0.68, 3.45) 
  P for trend   0.30  0.67  0.19 
Marine n-3/n-6 PUFAs      
  Q1 0.02 32/163 1.00 (reference) 22/163 1.00 (reference) 10/163 1.00 (reference) 
  Q2 0.03 57/203 1.38 (0.83, 2.29) 36/203 1.29 (0.71, 2.33) 21/203 1.49 (0.67, 3.35) 
  Q3 0.05 69/161 2.08 (1.26, 3.43) 53/161 2.28 (1.28, 4.04) 16/161 1.45 (0.62, 3.39) 
  Q4 0.07 39/134 1.48 (0.86, 2.58) 21/134 1.16 (0.59, 2.27) 18/134 2.12 (0.91, 4.94) 
  P for trend   <0.05  0.18  0.10 
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Abbreviations: Confidence interval (CI), Odds ratio (OR). 
a Unconditional logistic regression models were adjusted for age at interview, interview year, dialect group, body mass index, 
education, family history, diabetes at baseline, smoking, drinking, and physical activity.
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Table S5. Odds ratios and 95% confidence intervals for dietary polyunsaturated fatty acid (PUFA) intake and risk of colon 
and rectal cancer by GSTT1 and GSTM1 genotype  
 
 GSTT1 null GSTT1 positive  GSTM1 null GSTM1 positive 
 Case/ noncase OR
a (95% CI) Case/ noncase OR
a (95% CI)  Case/ noncase OR
a (95% CI) Case/ noncase OR
a (95% CI) 
COLON CANCER          
Total PUFAs          
  Q1 25/100 1.00 (reference) 38/165 1.00 (reference)  25/126 1.00 (reference) 38/139 1.00 (reference) 
  Q2 30/120 1.03 (0.54, 1.93) 42/176 1.10 (0.66, 1.84)  33/125 1.41 (0.76, 2.61) 39/171 0.93 (0.55, 1.57) 
  Q3 27/130 0.85 (0.44, 1.66) 53/156 1.55 (0.94, 2.55)  48/128 2.13 (1.18, 3.86) 32/158 0.79 (0.46, 1.37) 
  Q4 18/126 0.63 (0.31, 1.31) 38/194 0.92 (0.54, 1.56)  32/147 1.32 (0.70, 2.49) 24/173 0.55 (0.30, 0.99) 
  P for trend  0.18  0.89   0.21  0.04 
  P for interaction    0.14     0.02 
N-6 PUFAs          
  Q1 25/102 1.00 (reference) 39/167 1.00 (reference)  25/128 1.00 (reference) 39/141 1.00 (reference) 
  Q2 28/115 0.93 (0.49, 1.77) 41/174 1.02 (0.61, 1.69)  32/122 1.31 (0.71, 2.43) 37/167 0.85 (0.50, 1.43) 
  Q3 27/126 0.89 (0.46, 1.72) 51/162 1.44 (0.88, 2.36)  45/127 2.10 (1.16, 3.81) 33/161 0.79 (0.46, 1.37) 
  Q4 20/133 0.66 (0.32, 1.33) 40/188 0.97 (0.58, 1.62)  36/149 1.43 (0.77, 2.65) 24/172 0.54 (0.30, 0.96) 
  P for trend  0.25  0.75   0.13  0.04 
  P for interaction    0.17     0.01 
N-3 PUFAs          
  Q1 21/111 1.00 (reference) 50/162 1.00 (reference)  30/123 1.00 (reference) 41/150 1.00 (reference) 
  Q2 25/121 1.25 (0.63, 2.49) 40/173 0.74 (0.45, 1.21)  34/136 1.07 (0.60, 1.94) 31/158 0.71 (0.41, 1.24) 
  Q3 30/120 1.62 (0.82, 3.19) 38/169 0.73 (0.45, 1.21)  36/127 1.26 (0.70, 2.25) 32/162 0.76 (0.44, 1.30) 
  Q4 24/124 1.29 (0.63, 2.62) 43/187 0.75 (0.46, 1.22)  38/140 1.27 (0.71, 2.27) 29/171 0.61 (0.35, 1.06) 
  P for trend  0.38  0.27   0.35  0.11 
  P for interaction    0.20     0.09 
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 Table S5 (continued) 
 
 
 
 
 
 
 GSTT1 null GSTT1 positive  GSTM1 null GSTM1 positive 
(COLON CANCER) Case/ noncase OR
a (95% CI) Case/ noncase OR
a (95% CI)  Case/ noncase OR
a (95% CI) Case/ noncase OR
a (95% CI) 
Marine n-3 PUFAs          
  Q1 17/108 1.00 (reference) 48/168 1.00 (reference)  29/139 1.00 (reference) 36/137 1.00 (reference) 
  Q2 25/122 1.05 (0.51, 2.14) 43/183 0.84 (0.52, 1.36)  38/145 1.17 (0.66, 2.05) 30/160 0.67 (0.38, 1.17) 
  Q3 31/113 1.90 (0.95, 3.80) 39/172 0.76 (0.46, 1.24)  34/111 1.55 (0.86, 2.78) 36/174 0.69 (0.40, 1.19) 
  Q4 27/133 1.23 (0.61, 2.50) 41/168 0.86 (0.53, 1.40)  37/131 1.39 (0.78, 2.47) 31/170 0.62 (0.35, 1.08) 
  P for trend  0.30  0.47   0.18  0.12 
  P for interaction    0.17     0.06 
Marine n-3/n-6 
PUFAs          
  Q1 14/116 1.00 (reference) 45/189 1.00 (reference)  32/144 1.00 (reference) 27/161 1.00 (reference) 
  Q2 22/145 1.19 (0.56, 2.54) 42/177 1.07 (0.66, 1.74)  29/149 0.95 (0.53, 1.71) 35/173 1.17 (0.67, 2.07) 
  Q3 37/111 2.43 (1.20, 4.95) 45/162 1.15 (0.70, 1.87)  41/114 1.59 (0.91, 2.77) 41/159 1.34 (0.77, 2.34) 
  Q4 27/104 1.98 (0.94, 4.14) 39/163 0.96 (0.58, 1.60)  36/119 1.27 (0.71, 2.28) 30/148 1.05 (0.58, 1.89) 
  P for trend  0.01  0.99   0.18  0.76 
  P for interaction    0.01     0.46 
RECTAL CANCER          
Total PUFAs          
  Q1 21/100 1.00 (reference) 32/165 1.00 (reference)  26/126 1.00 (reference) 27/139 1.00 (reference) 
  Q2 24/120 1.08 (0.54, 2.15) 28/176 1.04 (0.58, 1.87)  25/125 1.27 (0.66, 2.45) 27/171 0.88 (0.48, 1.62) 
  Q3 16/130 0.75 (0.35, 1.61) 32/156 1.32 (0.74, 2.38)  19/128 0.97 (0.48, 1.96) 29/158 1.13 (0.60, 2.10) 
  Q4 21/126 1.03 (0.49, 2.14) 24/194 0.82 (0.44, 1.52)  22/147 1.06 (0.54, 2.09) 23/173 0.78 (0.41, 1.50) 
  P for trend  0.83  0.76   0.95  0.65 
  P for interaction    0.83     0.80 
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Table S5 (continued) 
 
 GSTT1 null GSTT1 positive  GSTM1 null GSTM1 positive 
(RECTAL CANCER) Case/ noncase OR
a (95% CI) Case/ noncase OR
a (95% CI)  Case/ noncase OR
a (95% CI) Case/ noncase OR
a (95% CI) 
N-6 PUFAs          
  Q1 21/102 1.00 (reference) 35/167 1.00 (reference)  29/128 1.00 (reference) 27/141 1.00 (reference) 
  Q2 20/115 0.91 (0.45, 1.86) 23/174 0.79 (0.43, 1.44)  17/122 0.75 (0.38, 1.50) 26/167 0.86 (0.46, 1.59) 
  Q3 21/126 1.09 (0.52, 2.26) 34/162 1.23 (0.70, 2.19)  24/127 1.20 (0.62, 2.34) 31/161 1.17 (0.63, 2.16) 
  Q4 20/133 0.94 (0.45, 1.96) 24/188 0.78 (0.42, 1.42)  22/149 0.92 (0.47, 1.80) 22/172 0.76 (0.39, 1.46) 
  P for trend  0.98  0.75   0.91  0.64 
  P for interaction    0.91     0.66 
N-3 PUFAs          
  Q1 19/111 1.00 (reference) 26/162 1.00 (reference)  22/123 1.00 (reference) 23/150 1.00 (reference) 
  Q2 16/121 1.02 (0.47, 2.20) 34/173 1.51 (0.83, 2.74)  21/136 1.14 (0.57, 2.30) 29/158 1.41 (0.74, 2.70) 
  Q3 28/120 1.71 (0.84, 3.46) 31/169 1.36 (0.74, 2.52)  26/127 1.48 (0.76, 2.92) 33/162 1.57 (0.84, 2.97) 
  Q4 19/124 1.25 (0.59, 2.67) 25/187 1.02 (0.54, 1.90)  23/140 1.31 (0.66, 2.62) 21/171 0.90 (0.46, 1.77) 
  P for trend  0.30  0.91   0.33  0.83 
  P for interaction    0.44     0.38 
Marine n-3 PUFAs          
  Q1 18/108 1.00 (reference) 24/168 1.00 (reference)  22/139 1.00 (reference) 20/137 1.00 (reference) 
  Q2 15/122 0.57 (0.26, 1.25) 26/183 1.10 (0.59, 2.06)  13/145 0.50 (0.24, 1.08) 28/160 1.28 (0.66, 2.47) 
  Q3 18/113 0.89 (0.41, 1.90) 37/172 1.55 (0.86, 2.80)  24/111 1.42 (0.73, 2.76) 30/174 1.15 (0.60, 2.19) 
  Q4 31/133 1.34 (0.67, 2.66) 30/168 1.30 (0.71, 2.40)  33/131 1.71 (0.91, 3.22) 28/170 1.06 (0.55, 2.04) 
  P for trend  0.18  0.24   0.01  1.00 
  P for interaction    0.68     0.07 
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Table S5 (continued) 
 
 GSTT1 null GSTT1 positive  GSTM1 null GSTM1 positive 
(RECTAL CANCER) Case/ noncase OR
a (95% CI) Case/ noncase OR
a (95% CI)  Case/ noncase OR
a (95% CI) Case/ noncase OR
a (95% CI) 
Marine n-3/n-6 PUFAs          
  Q1 14/116 1.00 (reference) 18/189 1.00 (reference)  17/144 1.00 (reference) 15/161 1.00 (reference) 
  Q2 18/145 1.12 (0.51, 2.44) 37/177 2.33 (1.23, 4.39)  20/149 1.29 (0.63, 2.63) 34/173 2.16 (1.09, 4.25) 
  Q3 24/111 1.63 (0.77, 3.47) 30/162 1.88 (0.97, 3.62)  25/114 1.76 (0.88, 3.55) 29/159 1.78 (0.89, 3.57) 
  Q4 26/104 1.93 (0.91, 4.08) 32/163 1.79 (0.93, 3.45)  30/119 1.81 (0.91, 3.60) 28/148 1.84 (0.91, 3.71) 
  P for trend  <0.05  0.20   0.06  0.21 
  P for interaction    0.30     0.61 
Abbreviations: Confidence interval (CI), Glutathione S-transferase theta 1 (GSTT1), Glutathione S-transferase mu 1 (GSTM1), Odds 
ratio (OR). 
a Unconditional logistic regression models were adjusted for sex, age at interview, interview year, dialect group, body mass index, 
education, family history, diabetes at baseline, smoking, drinking, and physical activity.
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Table S6. Odds ratios and 95% confidence intervals for dietary polyunsaturated fatty acid (PUFA) intake and risk of 
colorectal, colon and rectal cancer by GSTP1 genotype 
 
 GSTP1 Low activitya GSTP1 High activitya 
 Case/ noncase ORb (95% CI) Case/ noncase ORb (95% CI) 
COLORECTAL CANCER     
Total PUFAs     
  Q1 34/93 1.00 (reference) 82/172 1.00 (reference) 
  Q2 44/97 1.46 (0.82, 2.60) 80/199 0.96 (0.64, 1.42) 
  Q3 35/100 1.03 (0.56, 1.87) 93/186 1.26 (0.85, 1.87) 
  Q4 22/106 0.64 (0.33, 1.23) 79/214 0.92 (0.61, 1.38) 
  P for trend  0.11  0.99 
  P for interaction    0.15 
N-6 PUFAs     
  Q1 34/96 1.00 (reference) 86/173 1.00 (reference) 
  Q2 42/92 1.45 (0.82, 2.59) 70/197 0.78 (0.52, 1.16) 
  Q3 35/103 1.05 (0.58, 1.92) 98/185 1.29 (0.87, 1.90) 
  Q4 24/105 0.72 (0.38, 1.38) 80/216 0.86 (0.58, 1.28) 
  P for trend  0.23  0.95 
  P for interaction    0.26 
N-3 PUFAs     
  Q1 41/92 1.00 (reference) 75/181 1.00 (reference) 
  Q2 35/102 0.83 (0.47, 1.48) 80/192 1.12 (0.75, 1.67) 
  Q3 31/92 0.84 (0.46, 1.51) 96/197 1.34 (0.91, 1.99) 
  Q4 28/110 0.58 (0.32, 1.05) 83/201 1.19 (0.80, 1.79) 
  P for trend  0.09  0.28 
  P for interaction    0.05 
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Table S6 (continued) 
 
 GSTP1 Low activitya GSTP1 High activitya 
(COLORECTAL CANCER) Case/ noncase ORb (95% CI) Case/ noncase ORb (95% CI) 
Marine n-3 PUFAs     
  Q1 33/91 1.00 (reference) 74/185 1.00 (reference) 
  Q2 34/96 0.80 (0.44, 1.46) 75/209 0.93 (0.63, 1.39) 
  Q3 37/98 0.89 (0.49, 1.60) 87/187 1.23 (0.83, 1.82) 
  Q4 31/111 0.59 (0.32, 1.08) 98/190 1.39 (0.95, 2.04) 
  P for trend  0.13  0.04 
  P for interaction    0.03 
Marine n-3/n-6 PUFAs     
  Q1 29/107 1.00 (reference) 62/198 1.00 (reference) 
  Q2 34/95 1.23 (0.67, 2.25) 84/227 1.29 (0.87, 1.93) 
  Q3 38/94 1.33 (0.73, 2.41) 98/179 1.73 (1.16, 2.58) 
  Q4 34/100 0.93 (0.50, 1.70) 90/167 1.68 (1.12, 2.54) 
  P for trend  0.86  <0.01 
  P for interaction    0.14 
COLON CANCER     
Total PUFAs     
  Q1 20/93 1.00 (reference) 43/172 1.00 (reference) 
  Q2 28/97 1.50 (0.75, 3.01) 44/199 0.95 (0.58, 1.54) 
  Q3 23/100 1.06 (0.52, 2.17) 57/186 1.40 (0.87, 2.26) 
  Q4 10/106 0.45 (0.19, 1.08) 46/214 0.95 (0.58, 1.56) 
  P for trend  0.07  0.77 
  P for interaction    0.09 
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Table S6 (continued) 
 
 GSTP1 Low activitya GSTP1 High activitya 
(COLON CANCER) Case/ noncase ORb (95% CI) Case/ noncase ORb (95% CI) 
N-6 PUFAs     
  Q1 20/96 1.00 (reference) 44/173 1.00 (reference) 
  Q2 27/92 1.44 (0.72, 2.88) 42/197 0.86 (0.52, 1.40) 
  Q3 21/103 0.95 (0.46, 1.97) 57/185 1.40 (0.87, 2.24) 
  Q4 13/105 0.59 (0.26, 1.34) 47/216 0.92 (0.56, 1.51) 
  P for trend  0.14  0.76 
  P for interaction    0.18 
N-3 PUFAs     
  Q1 30/92 1.00 (reference) 41/181 1.00 (reference) 
  Q2 18/102 0.54 (0.27, 1.08) 47/192 1.15 (0.70, 1.88) 
  Q3 17/92 0.60 (0.29, 1.22) 51/197 1.25 (0.77, 2.04) 
  Q4 16/110 0.43 (0.21, 0.87) 51/201 1.26 (0.78, 2.06) 
  P for trend  0.03  0.32 
  P for interaction    0.03 
Marine n-3 PUFAs     
  Q1 22/91 1.00 (reference) 43/185 1.00 (reference) 
  Q2 22/96 0.66 (0.32, 1.35) 46/209 0.97 (0.60, 1.57) 
  Q3 21/98 0.76 (0.37, 1.54) 49/187 1.14 (0.71, 1.84) 
  Q4 16/111 0.44 (0.21, 0.94) 52/190 1.23 (0.77, 1.98) 
  P for trend  0.06  0.29 
  P for interaction    <0.05 
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Table S6 (continued) 
 
 GSTP1 Low activitya GSTP1 High activitya 
(COLON CANCER) Case/ noncase ORb (95% CI) Case/ noncase ORb (95% CI) 
Marine n-3/n-6 PUFAs     
  Q1 18/107 1.00 (reference) 41/198 1.00 (reference) 
  Q2 20/95 1.07 (0.51, 2.24) 44/227 1.02 (0.63, 1.66) 
  Q3 24/94 1.35 (0.66, 2.78) 58/179 1.50 (0.94, 2.40) 
  Q4 19/100 0.90 (0.42, 1.90) 47/167 1.35 (0.83, 2.21) 
  P for trend  0.93  0.09 
  P for interaction    0.37 
RECTAL CANCER     
Total PUFAs     
  Q1 14/93 1.00 (reference) 39/172 1.00 (reference) 
  Q2 16/97 1.28 (0.55, 2.96) 36/199 0.93 (0.55, 1.57) 
  Q3 12/100 0.89 (0.36, 2.20) 36/186 1.04 (0.60, 1.80) 
  Q4 12/106 0.85 (0.35, 2.10) 33/214 0.86 (0.49, 1.49) 
  P for trend  0.57  0.70 
  P for interaction    0.75 
N-6 PUFAs     
  Q1 14/96 1.00 (reference) 42/173 1.00 (reference) 
  Q2 15/92 1.27 (0.54, 2.98) 28/197 0.66 (0.38, 1.14) 
  Q3 14/103 1.11 (0.46, 2.67) 41/185 1.12 (0.66, 1.90) 
  Q4 11/105 0.86 (0.34, 2.15) 33/216 0.77 (0.45, 1.33) 
  P for trend  0.70  0.73 
  P for interaction    0.80 
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Table S6 (continued) 
 
 GSTP1 Low activitya GSTP1 High activitya 
(RECTAL CANCER) Case/ noncase ORb (95% CI) Case/ noncase ORb (95% CI) 
N-3 PUFAs     
  Q1 11/92 1.00 (reference) 34/181 1.00 (reference) 
  Q2 17/102 1.71 (0.71, 4.14) 33/192 1.11 (0.63, 1.95) 
  Q3 14/92 1.62 (0.65, 4.03) 45/197 1.52 (0.89, 2.61) 
  Q4 12/110 0.90 (0.35, 2.31) 32/201 1.12 (0.63, 1.98) 
  P for trend  0.72  0.46 
  P for interaction    0.58 
Marine n-3 PUFAs     
  Q1 11/91 1.00 (reference) 31/185 1.00 (reference) 
  Q2 12/96 0.92 (0.37, 2.32) 29/209 0.85 (0.47, 1.51) 
  Q3 16/98 1.24 (0.51, 2.98) 38/187 1.29 (0.75, 2.23) 
  Q4 15/111 0.84 (0.34, 2.06) 46/190 1.65 (0.97, 2.80) 
  P for trend  0.84  0.02 
  P for interaction    0.23 
Marine n-3/n-6 PUFAs     
  Q1 11/107 1.00 (reference) 21/198 1.00 (reference) 
  Q2 14/95 1.47 (0.61, 3.55) 40/227 1.89 (1.05, 3.41) 
  Q3 14/94 1.25 (0.51, 3.04) 40/179 2.08 (1.15, 3.77) 
  Q4 15/100 0.98 (0.40, 2.38) 43/167 2.52 (1.39, 4.58) 
  P for trend  0.84  <0.01 
  P for interaction    0.12 
Abbreviations: Confidence interval (CI), Glutathione S-transferase pi 1 (GSTP1), Odds ratio (OR). 
a GSTP1 Low activity was defined as GSTP1 AB/BB; GSTP1 High activity was defined as GSTP1 AA. 
b Unconditional logistic regression models were adjusted for sex, age at interview, interview year, dialect group, body mass index, 
education, family history, diabetes at baseline, smoking, drinking, and physical activity. 
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